Method of analyzing nucleic acids from single cell or population of cells
By using nucleic acid barcode sequence identification and microfluidic technology to process nucleic acids in single cells or small cell populations in discrete partitions, the problem of difficulty in identifying and characterizing small cell populations in existing technologies has been solved, achieving high-throughput and accurate nucleic acid sequencing and attribution.
Patent Information
- Application Number
- CN202411119807.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2014-10-08
- Filing Date
- 2015-06-26
- Publication Date
- 2024-11-08
AI Technical Summary
Existing nucleic acid sequencing technologies are unable to effectively identify and characterize a small number of cell subpopulations in biological samples. Overall sample preparation methods cannot be accurately attributed to specific cell sets, and next-generation sequencing systems have high requirements for DNA input, making it difficult to handle extremely low amounts of nucleic acid from single cells or small cell populations.
By assigning nucleic acids from single cells or small cell populations to discrete partitions, identifying and characterizing them using oligonucleotides containing nucleic acid barcode sequences, and combining microfluidics and microcapsule encapsulation, the compartmentalization and barcoding of nucleic acids are achieved, ensuring the unique identification of each partition. Subsequently, nucleic acids are assigned to individual cells via sequencing.
This invention enables a high-throughput, non-amplified single-molecule method for single cells or small cell populations, capable of processing extremely low amounts of nucleic acids and accurately assigning them to specific cells. It solves the problem of identifying and characterizing small cell populations in existing technologies, and improves the accuracy and efficiency of sequencing.
Smart Images

Figure CN118910216A_ABST
Abstract
Description
[0001] This application is a divisional application of a Chinese patent application with an application date of June 26, 2015, application number 202110541753.3, and invention name “Method for analyzing nucleic acids from a single cell or a cell population”.
[0002] The application with the application date of June 26, 2015, application number 202110541753.3, and invention name “Method for analyzing nucleic acids from a single cell or a cell population” is a divisional application of the Chinese patent application with the application date of June 26, 2015, application number 201580034263.7, and invention name “Method for analyzing nucleic acids from a single cell or a cell population” (the corresponding PCT application with the application date of June 26, 2015 and application number PCT / US2015 / 038178).
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims priority to U.S. Provisional Patent Application No. 62 / 017,558, filed on June 26, 2014, and U.S. Provisional Patent Application No. 62 / 061,567, filed on October 8, 2014, each of which is incorporated herein by reference in its entirety for all purposes. background
[0006] Remarkable advances in the analysis and characterization of biological and biochemical materials and systems have led to unprecedented advances in the understanding of mechanisms of life, health, disease, and treatment. Among these advances, technologies to target and characterize the genomic makeup of biological systems have produced some of the most groundbreaking results, including advances in the use and development of gene amplification techniques and nucleic acid sequencing technologies.
[0007] Nucleic acid sequencing can be used to obtain information in a variety of biomedical contexts, including diagnosis, prognosis, biotechnology, and forensic biology. Sequencing may involve: basic methods, including Maxam-Gilbert sequencing and chain termination; or de novo sequencing methods, including shotgun sequencing and bridge PCR; or next-generation methods, including polymerase clone sequencing, 454 pyrosequencing, Illumina sequencing, SOLiD sequencing, Ion Torrent semiconductor sequencing, HeliScope single molecule sequencing, Sequencing, etc.
[0008] Despite these advances in biological characterization, many challenges remain unsolved or are relatively poorly solved by solutions offered today. The present disclosure provides novel solutions and approaches for addressing many of the deficiencies of the prior art.
[0009] Brief Description
[0010] Provided herein are methods, compositions, and systems for analyzing single cells or small populations of cells, including analyzing nucleic acids from these single cells or cell populations and attributing nucleic acids to these single cells or cell populations.
[0011] One aspect of the present disclosure provides a method for analyzing nucleic acids from a cell, comprising providing nucleic acids originating from a single cell into discrete partitions; generating one or more first nucleic acid sequences originating from the nucleic acids within the discrete partitions, the one or more first nucleic acid sequences having been linked to an oligonucleotide comprising a common nucleic acid barcode sequence; generating a representation of the one or more first nucleic acid sequences or one or more second nucleic acid sequences originating from the one or more first nucleic acid sequences, the one or more second nucleic acid sequences comprising the common barcode sequence; and identifying the one or more first nucleic acid sequences or one or more second nucleic acid sequences as originating from the single cell based at least in part on the presence of the common nucleic acid barcode sequence in the generated representation.
[0012] In some embodiments, the discrete partitions are discrete droplets. In some embodiments, the oligonucleotides are co-partitioned with nucleic acids derived from a single cell into the discrete partitions. In some embodiments, at least 10,000, at least 100,000, or at least 500,000 of the oligonucleotides are co-partitioned with nucleic acids derived from a single cell into the discrete partitions.
[0013] In some embodiments, oligonucleotides connected to beads are provided, wherein each oligonucleotide on the beads comprises the same barcode sequence, and the beads and individual cells are co-assigned to discrete partitions. In some embodiments, the oligonucleotides are releasably connected to beads. In some embodiments, beads include degradable beads. In some embodiments, before or during the generation of one or more first nucleic acid sequences, the method includes releasing the oligonucleotides from the beads via degraded beads. In some embodiments, before generating characterization, the method includes releasing one or more first nucleic acid sequences from discrete partitions.
[0014] In some embodiments, generating the characterization comprises sequencing one or more first nucleic acid sequences or one or more second nucleic acid sequences. The method may further comprise assembling a contiguous nucleic acid sequence of at least a portion of the genome of the single cell from a sequence of the one or more first nucleic acid sequences or the one or more second nucleic acid sequences. In addition, the method may further comprise characterizing the single cell based on the nucleic acid sequence of at least a portion of the genome of the single cell.
[0015] In some embodiments, nucleic acid is released from a single cell in a discrete partition. In some embodiments, nucleic acid includes ribonucleic acid (RNA), such as messenger RNA (mRNA). In some embodiments, producing one or more first nucleic acid sequences includes making nucleic acid reverse transcribe under the conditions of producing one or more first nucleic acid sequences. In some embodiments, reverse transcription is carried out in discrete partitions. In some embodiments, oligonucleotides are provided in discrete partitions and include poly-thymidylic acid (poly-T) sequences. In some embodiments, reverse transcription includes making at least a portion of each of poly-thymidylic acid sequences hybridize with nucleic acid and extending poly-thymidylic acid sequences in a template-directed manner. In some embodiments, oligonucleotides include anchor sequences that promote the hybridization of poly-thymidylic acid sequences. In some embodiments, oligonucleotides include random guide sequences, which can be, for example, random hexamer. In some embodiments, reverse transcription includes making at least a portion of each of random guide sequences hybridize with nucleic acid and extending random guide sequences in a template-directed manner.
[0016] In some embodiments, at least a portion of a given person in one or more first nucleic acid sequences has sequence complementarity with a given person in nucleic acid. In some embodiments, discrete partitions include a single cell among a plurality of cells at most. In some embodiments, oligonucleotides include unique molecular sequence segments. In some embodiments, the method may include identifying a single nucleic acid sequence of one or more first nucleic acid sequences or one or more second nucleic acid sequences as a given nucleic acid derived from nucleic acid at least in part based on the presence of a unique molecular sequence segment. In some embodiments, the method includes determining the amount of a given nucleic acid based on the presence of a unique molecular sequence segment.
[0017] In some embodiments, the method includes adding one or more additional sequences to one or more first nucleic acid sequences to produce one or more second nucleic acid sequences before generating the characterization. In some embodiments, the method includes adding the first additional nucleic acid sequence to the one or more first nucleic acid sequences with the assistance of a conversion oligonucleotide. In some embodiments, the conversion oligonucleotide hybridizes with at least a portion of the one or more first nucleic acid sequences, and extends in a template-directed manner to couple the first additional nucleic acid sequence to the one or more first nucleic acid sequences. In some embodiments, the method includes amplifying the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence. In some embodiments, the amplification is performed in discrete partitions. In some embodiments, the amplification is performed after releasing the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence from the discrete partitions.
[0018] In some embodiments, after amplification, the method includes adding one or more second additional nucleic acid sequences to one or more first nucleic acid sequences coupled to the first additional sequence to produce one or more second nucleic acid sequences. In some embodiments, adding the one or more second additional sequences includes removing a portion of each of the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence and coupling it to the one or more second additional nucleic acid sequences. In some embodiments, the removal is accomplished by shearing the one or more first nucleic acid sequences coupled (e.g., connected) to the first additional nucleic acid sequence.
[0019] In some embodiments, before generating the characterization, the method includes causing one or more first nucleic acid sequences to be transcribed to produce one or more RNA fragments. In some embodiments, transcription is performed after causing one or more first nucleic acid sequences to be released from discrete partitions. In some embodiments, the oligonucleotide comprises a T7 promoter sequence. In some embodiments, before generating the characterization, the method includes removing a portion of each of the one or more RNA sequences and coupling the additional sequence to the one or more RNA sequences. In some embodiments, before generating the characterization, the method includes causing one or more RNA sequences coupled to the additional sequence to be reverse transcribed to produce one or more second nucleic acid sequences. In some embodiments, before generating the characterization, the method includes amplifying one or more second nucleic acid sequences. In some embodiments, before generating the characterization, the method includes causing one or more RNA sequences to be reverse transcribed to produce one or more DNA sequences. In some embodiments, before generating the characterization, the method includes removing a portion of each of the one or more DNA sequences and coupling the one or more additional sequences to the one or more DNA sequences to produce one or more second nucleic acid sequences. In some embodiments, before generating the characterization, the method includes amplifying one or more second nucleic acid sequences.
[0020] In some embodiments, the nucleic acid comprises a complementary (cDNA) produced by reverse transcription of RNA of a single cell. In some embodiments, the oligonucleotide comprises a guide sequence and is provided in a discrete partition. In some embodiments, the guide sequence comprises a random N-mer. In some embodiments, generating one or more first nucleic acid sequences comprises hybridizing the guide sequence with the cDNA and extending the guide sequence in a template-directed manner.
[0021] In some embodiments, discrete partitions include conversion oligonucleotides containing complementary sequences of oligonucleotides. In some embodiments, generating one or more first nucleic acid sequences includes making conversion oligonucleotides hybridize with at least a portion of nucleic acid fragments derived from nucleic acid and extending conversion oligonucleotides in a template-directed manner. In some embodiments, generating one or more first nucleic acid sequences includes connecting oligonucleotides to one or more first nucleic acid sequences. In some embodiments, one or more first nucleic acid sequences are nucleic acid fragments derived from nucleic acid. In some embodiments, generating one or more first nucleic acid sequences includes coupling oligonucleotides to nucleic acid (e.g., connecting).
[0022] In some embodiments, multiple partitions include discrete partitions. In some embodiments, multiple partitions contain less than one cell per partition on average. In some embodiments, less than 25% of the partitions in multiple partitions do not contain cells. In some embodiments, multiple partitions include discrete partitions including cells with at least one assignment. In some embodiments, less than 25%, less than 20%, less than 15%, less than 10%, less than 5% or less than 1% of discrete partitions contain more than one cell. In some embodiments, at least a subset of discrete partitions contain beads. In some embodiments, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% of discrete partitions contain at least one cell and at least one bead. In some embodiments, discrete partitions contain assigned nucleic acid barcode sequences. In some embodiments, discrete partitions contain at least 1,000, at least 10,000 or at least 100,000 different assigned nucleic acid barcode sequences. In some embodiments, the plurality of partitions includes at least 1,000, at least 10,000, or at least 100,000 partitions.
[0023] In another aspect, the present disclosure provides a method of characterizing cells in a population of multiple different cell types, comprising providing nucleic acid from a single cell in the population into discrete partitions; ligating oligonucleotides comprising a common nucleic acid barcode sequence to one or more fragments of nucleic acid from the single cell within the discrete partitions, wherein the multiple different partitions comprise different common nucleic acid barcode sequences; and characterizing the one or more fragments of nucleic acid from the multiple discrete partitions and attributing the one or more fragments to a single cell based at least in part on the presence of the common barcode sequence; and characterizing the multiple single cells in the population based on the characterization of the one or more fragments in the multiple discrete partitions.
[0024] In some embodiments, the method includes fragmenting the nucleic acid. In some embodiments, the discrete partitions are droplets. In some embodiments, characterizing one or more fragments of nucleic acid includes sequencing the ribosomal deoxyribonucleic acid of a single cell, and characterizing the cell includes identifying the cell genus, species, strain or variant. In some embodiments, the single cell is derived from a microbiome sample. In some embodiments, the single cell is derived from a human tissue sample. In some embodiments, the single cell is derived from a circulating cell in a mammal. In some embodiments, the single cell is derived from a forensic sample. In some embodiments, the nucleic acid is released from a single cell in a discrete partition.
[0025] Additional aspects of the present disclosure provide methods for characterizing a single cell or a population of cells, comprising incubating cells with a plurality of different cell surface feature binding base types under conditions that allow binding between one or more cell surface feature binding bases and their respective cell surface features (if present), wherein each different cell surface binding base type is capable of binding to a different cell surface feature, and wherein each different cell surface binding base type comprises a reporter oligonucleotide associated therewith; partitioning the cells into partitions comprising a plurality of oligonucleotides containing barcode sequences; linking the barcode sequences to oligonucleotide reporters present in the partitions; sequencing the oligonucleotide reporters and the linked barcodes; and characterizing the cell surface features present on the cells based on the sequenced reporter oligonucleotides.
[0026] Additional aspects of the present disclosure provide a composition comprising a plurality of partitions, each of which comprises a single cell and an oligonucleotide population comprising a common nucleic acid barcode sequence. In some embodiments, the plurality of partitions comprises droplets in an emulsion. In some embodiments, the oligonucleotide population within each of the plurality of partitions is coupled to beads disposed within each of the plurality of partitions. In some embodiments, a single cell has been associated with a plurality of different cell surface feature binding bases associated with respective cell surface features, and various types of cell surface feature binding bases comprise oligonucleotide reporter bases containing different nucleotide sequences. In some embodiments, a plurality of different cell surface feature binding bases comprise a plurality of different antibodies or antibody fragments having binding affinity to a plurality of different cell surface features.
[0027] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Therefore, the drawings and descriptions are to be regarded as illustrative in nature, rather than restrictive.
[0028] Incorporated by Reference
[0029] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event that publications and patents or patent applications incorporated by reference conflict with the disclosure contained in this specification, the specification is intended to supersede and / or take precedence over any such conflicting material. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description of illustrative embodiments that use the principles of the present invention and the accompanying drawings (also referred to herein as "Figures" and "FIG."), in which:
[0032] Figure 1 Schematic illustration of the microfluidic channel structure used to distribute single cells or small groups of cells.
[0033] Figure 2 Schematic illustration of the microfluidic channel structure used for co-dispensing of cells and beads or microcapsules containing additional reagents.
[0034] Figure 3 An exemplary method for amplifying and barcoding nucleic acids of cells is schematically illustrated.
[0035] Figure 4 A schematic illustration of the use of barcoding of nucleic acids of cells for characterization thereof in attributing sequence data to individual cells or groups of cells is provided.
[0036] Figure 5 A schematic diagram illustrating the association of cells with labeled cell-binding ligands is provided.
[0037] Figure 6 A schematic illustration of an exemplary workflow for RNA analysis using the methods described herein is provided.
[0038] Figure 7 Schematic illustrations of exemplary barcoded oligonucleotide structures for analysis of ribonucleic acid (RNA) using the methods described herein are provided.
[0039] Figure 8 Provides images of single cells co-distributed with a single barcoded bead.
[0040] Fig.9A-E provides schematic illustrations of exemplary barcoded oligonucleotide structures for analysis of RNA and exemplary procedures for performing RNA analysis.
[0041] Fig.10 Schematic illustrations of exemplary barcoded oligonucleotide structures for exemplary analysis of RNA and use of the sequences for in vitro transcription are provided.
[0042] Fig.11 Schematic illustrations of exemplary barcoded oligonucleotide structures for analysis of RNA and exemplary procedures for performing RNA analysis are provided.
[0043] Fig. 12A -B provides a schematic illustration of an exemplary barcoded oligonucleotide structure for analysis of RNA.
[0044] Fig.13A -C provides an illustration of exemplary yields of template-switching reverse transcription and PCR in the partition.
[0045] Fig.14A -B provides an illustration of exemplary yields of reverse transcription and cDNA amplification in partitions with varying cell numbers.
[0046] Fig.15 An illustration of exemplary yields of cDNA synthesis and real-time quantitative PCR at different input cell concentrations and the effect of different primer concentrations on yield at fixed cell input concentration is provided.
[0047] Fig.16 An illustration of exemplary yields of in vitro transcription is provided.
[0048] Fig.17 An exemplary computer control system that is programmed or otherwise configured to implement the methodologies provided herein is shown. Detailed Description
[0050] Although various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, changes, and substitutions will occur to those skilled in the art without departing from the scope of the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed.
[0051] Where values are described as ranges, it should be understood that such disclosure includes disclosure of all possible sub-ranges within such ranges, as well as specific values within such ranges, whether or not a specific value or a specific sub-range is explicitly stated.
[0052] I. Single Cell Analysis
[0053] Advanced nucleic acid sequencing technologies have produced important results in sequencing biological materials, including providing large amounts of sequence information about individual organisms as well as relatively pure biological samples. However, these systems have not proven effective in being able to identify and characterize smaller minority cell subpopulations in biological samples that are representative of the overall composition of the sample, but for which individualized sequence information may prove to be even more valuable.
[0054] Most nucleic acid sequencing techniques derive that the nucleic acid sequenced is from a collection of cells obtained from tissues or other samples. Cells can be processed as a whole to extract the gene material representing the general situation of a cell colony, and then the gene material can be processed into a DNA library ready for sequencing, which is configured for a given sequencing technique. As will be appreciated, although often discussed with respect to DNA or nucleic acid, the nucleic acid derived from a cell may include DNA or RNA, including, for example, mRNA, total RNA, etc., which may be processed to produce cDNA, so as to, for example, use any of a variety of RNA-seq methods to sequence. After this processing, in such an overall method, in the absence of cell-specific markers, it is in fact impossible to attribute the gene material to the contribution of a subset of cells or all cells in the sample.
[0055] Except feature can not be attributed to the specific subset of cell colony, this type of overall sample preparation method also tends to mainly identify and characterize the majority components in the cell sample from the beginning, and is not designed to single out a minority component, such as the gene material contributed by the smaller percentage in a cell, several cells or all cells in the sample. Similarly, in the case of analyzing the expression level of mRNA for example, overall method will tend to potentially present very inaccurate data by a non-homogeneous cell colony with respect to expression level. In some cases, in the case where the expression in the less minority cell in the analyzed colony is high and the expression in the majority cell in the colony does not exist, overall method will indicate the low-level expression of the whole colony.
[0056] This original majority bias is further amplified and even overwhelming by the processing operations used when establishing sequencing libraries from these samples. Specifically, most next-generation sequencing technologies rely on geometric amplification of nucleic acid fragments, such as polymerase chain reaction, to produce enough DNA for sequencing libraries. However, such geometric amplification is biased towards amplifying the majority components in the sample, and may not retain the starting ratio of such minority and majority components. For example, due to comparative exponential amplification (repeated doublings of higher concentrations quickly exceed repeated doublings of smaller components) and due to the isolation of amplification reagents and resources (because larger components are amplified, they preferentially utilize primers and other amplification reagents), if the sample includes 95% of the DNA from a specific cell type (e.g., host tissue cells) in the sample and 5% of the DNA from another cell type (e.g., cancer cells), then PCR-based amplification may preferentially amplify the majority DNA rather than the minority DNA.
[0057] While some of these difficulties can be addressed by utilizing different sequencing systems, such as single-molecule systems that do not require amplification, the overall sequencing methods of single-molecule systems and other next-generation sequencing systems may also have requirements for sufficiently large input DNA requirements. Specifically, single-molecule sequencing systems such as the Pacific Biosciences SMRT sequencing system may have sample input DNA requirements of 500 nanograms (ng) up to 10 micrograms (μg), which is much larger than can be obtained from a single cell or even a small subpopulation of cells. Similarly, other NGS systems may be optimized for sample DNA starting amounts of about 50 ng to about 1 μg in the sample.
[0058] II. Compartmentalization and Characterization of Cells
[0059] However, disclosed herein are methods and systems for characterizing nucleic acids from small cell populations, particularly in the context of larger cell populations, and in some cases from single cells. The methods and systems provide the advantages of being able to provide the attribution advantages of non-amplified single molecule methods with high throughput of other next generation systems, and the additional advantage of being able to process and sequence extremely low amounts of input nucleic acids that may be derived from a single cell or a collection of small cells.
[0060] In particular, the methods described herein will include, for example, compartmentalization of the analysis of a single cell or small cell population of nucleic acids from a single cell or small cell population, and then allow the analysis to be attributed back to the single cell or small cell population from which the nucleic acid originated. This can be achieved regardless of whether the cell population is a 50 / 50 mixture representing a cell type, a 90 / 10 mixture of a cell type, or indeed any ratio of a cell type and a completely heterogeneous mixture of different cell types or any mixture between these. Different cell types can include cells or organisms from different tissue types of an individual, from different individuals, from different genera, species, strains, variants, or any combination of any or all of the above. For example, different cell types can include normal tissue and tumor tissue from an individual; a variety of different bacterial species, strains, and / or variants from environmental, forensic, microbial groups, or other samples; or any of a variety of other mixtures of cell types.
[0061] In one aspect, the methods and systems described herein provide for compartmentalization, precipitation or partitioning of nucleic acid contents of individual cells from a sample material containing cells into discrete compartments or partitions (interchangeably referred to herein as partitions), wherein each partition maintains its own contents separate from the contents of other partitions. A unique identifier (e.g., a barcode) may be delivered previously, subsequently, or simultaneously to the partition housing the compartmentalized or partitioned cells to allow subsequent attribution of characteristics of individual cells to specific compartments.
[0062] As used herein, in some aspects, a partition refers to a vessel or container (such as a hole, microwell, tube, through-hole or other vessel in a nanoarray substrate (e.g., BioTrove nanoarray)). However, in many aspects, a compartment or partition includes a partition that can flow within a fluid stream. These partitions may include, for example, microcapsules or microvesicles having an outer barrier surrounding an inner fluid center or core, or they may be a porous matrix capable of entraining and / or retaining materials within the matrix. However, in some aspects, these partitions include droplets of an aqueous fluid within a non-aqueous continuous phase (e.g., an oil phase). A variety of different containers are described, for example, in U.S. Patent Application No. 13 / 966,150 filed on August 13, 2013, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes. Similarly, emulsion systems for forming stable droplets in non-aqueous or oily continuous phases are described in detail, for example, in U.S. Patent Publication No. 2010 / 0105112, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes.
[0063] In the case of droplets in an emulsion, the assignment of individual cells to discrete partitions can generally be achieved in the following manner: the flow stream of cells in an aqueous fluid is introduced into the flow stream of a non-aqueous fluid so that droplets are produced at the joint of the two streams. By providing an aqueous cell-containing stream at a certain cell concentration level, the occupancy level of the resulting partition in terms of the number of cells can be controlled. In some cases, in the case of a single cell partition being required, the relative flow rate of the fluid may need to be controlled so that the partition contains less than one cell on average per partition to ensure that those occupied partitions are mainly single occupied. Similarly, it may be desirable to control the flow rate so that a higher percentage of the partition is occupied, thereby, for example, only allowing a smaller percentage of unoccupied partitions. In some aspects, control flow and channel structure to ensure the desired number of single occupied partitions, unoccupied partitions below a certain level, and multiple occupied partitions below a certain level.
[0064] In many cases, the systems and methods are used to ensure that the vast majority of occupied partitions (partitions containing one or more microcapsules) include no more than 1 cell per occupied partition. In some cases, the dispensing process is controlled so that less than 25% of the occupied partitions contain more than one cell, and in many cases less than 20% of the occupied partitions have more than one cell, and in some cases less than 10% or even less than 5% of the occupied partitions include more than one cell per partition.
[0065] Additionally or alternatively, in many cases, it is necessary to avoid forming too many empty partitions. Although this can be achieved by providing a sufficient number of cells into the distribution area, a Poissonian distribution is expected to increase the number of partitions that will include multiple cells. Therefore, according to the aspects described herein, the flow rate of one or more cells or other fluids directed to the distribution area is controlled so that in many cases, no more than 50% of the generated partitions are unoccupied, i.e., including less than 1 cell, no more than 25% of the generated partitions, and no more than 10% of the generated partitions may be unoccupied. In addition, in some aspects, these flows are controlled to present a non-Poisson distribution of a single occupied partition while providing a lower level of unoccupied partitions. Again, in some aspects, unoccupied partitions of the range mentioned above can be achieved while still providing any of the single occupancy rates described above. For example, in many cases, the systems and methods described herein are used to form resulting partitions having multiple occupancy rates of less than 25%, less than 20%, less than 15%, less than 10%, and in many cases less than 5%, while having unoccupied partitions of less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, and in some cases less than 5%.
[0066] As will be appreciated, the occupancy described above may also be applicable to partitions comprising both cells and beads carrying barcode oligonucleotides. Specifically, in some aspects, a considerable proportion of all occupied partitions will include both beads and cells. Specifically, it may be necessary to make at least 50% of the partitions occupied by at least one cell and at least one bead, or at least 75% of the partitions may be so occupied, or even at least 80% or at least 90% of the partitions may be so occupied. In addition, in those cases where a single cell and a single bead need to be provided in a partition, at least 50% of the partitions may be so occupied, and at least 60%, at least 70%, at least 80% or even at least 90% of the partitions may be so occupied.
[0067] Although described above with respect to providing generally singly occupied partitions, in some cases it may be desirable to provide, for example, multiple occupied partitions containing two, three, four or more cells and / or beads within a single partition. Thus, as mentioned above, the flow characteristics of the fluid containing cells and / or beads and the distribution fluid may be controlled to provide such multiple occupied partitions. In particular, the flow parameters may be controlled to provide an occupancy of greater than 50%, greater than 75%, and in some cases greater than 80%, 90%, 95% or more of the partition.
[0068] Additionally, in many cases, multiple beads within a single partition may contain different agents associated therewith. In such cases, it may be advantageous to introduce different beads from different sources of beads (i.e., containing different agents associated therewith) into such a common channel or droplet generation adapter through different channel inlets that enter such a common channel or droplet generation adapter. In such cases, the flow rate and frequency of different beads entering the channel or adapter can be controlled to provide a desired ratio of microcapsules from each source while ensuring that the desired pairing or combination of such beads enters a partition having a desired number of cells.
[0069] The partitions described herein are often characterized as having extremely small volumes, e.g., less than 10 μL, less than 5 μL, less than 1 μL, less than 900 picoliters (pL), less than 800 pL, less than 700 pL, less than 600 pL, less than 500 pL, less than 400 pL, less than 300 pL, less than 200 pL, less than 100 pL, less than 50 pL, less than 20 pL, less than 10 pL, less than 1 pL, less than 500 nanoliters (nL), or even less than 100 nL, 50 nL, or even smaller.
[0070] For example, in the case of droplet-based partitioning, the droplets may have a total volume of less than 1000 pL, less than 900 pL, less than 800 pL, less than 700 pL, less than 600 pL, less than 500 pL, less than 400 pL, less than 300 pL, less than 200 pL, less than 100 pL, less than 50 pL, less than 20 pL, less than 10 pL, or even less than 1 pL. In the case of co-partitioning with beads, it will be appreciated that the volume of sample fluid within a partition, e.g., including co-partitioned cells, may be less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or even less than 10% of the volumes described above.
[0071] As described elsewhere herein, the distribution of materials can produce a partition population. In such cases, any appropriate number of partitions can be produced to produce a partition population. For example, in the methods described herein, a partition population comprising at least about 1,000 partitions, at least about 5,000 partitions, at least about 10,000 partitions, at least about 50,000 partitions, at least about 100,000 partitions, at least about 500,000 partitions, at least about 1,000,000 partitions, at least about 5,000,000 partitions, at least about 10,000,000 partitions, at least about 50,000,000 partitions, at least about 100,000,000 partitions, at least about 500,000,000 partitions, or at least about 1,000,000,000 partitions can be produced. In addition, a partition population can include both unoccupied partitions (e.g., empty partitions) and occupied partitions.
[0072] In some cases, microfluidic channel networks are particularly suitable for generating partitions as described herein. Examples of such microfluidic devices include those described in detail in Provisional U.S. Patent Application No. 61 / 977,804 filed on April 4, 2014, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes. Alternative mechanisms may also be employed when distributing individual cells, including porous membranes through which an aqueous mixture of cells is squeezed into a non-aqueous fluid. Such systems are generally available from, for example, Nanomi, Inc.
[0073] Figure 1In the example of the simplified microfluidic channel structure for distributing a single cell, it is described. As described elsewhere herein, in some cases, each occupied subdistrict of most occupied subdistricts includes no more than one cell, and in some cases, some produced subdistricts are not occupied. However, in some cases, some occupied subdistricts may include more than one cell. In some cases, the distribution process can be controlled so that less than 25% of the occupied subdistricts contain more than one cell, and in many cases, less than 20% of the occupied subdistricts have more than one cell, and in some cases, less than 10% or even less than 5% of the occupied subdistricts each subdistrict includes more than one cell. As shown in the figure, the channel structure may include channel sections 102, 104, 106 and 108 connected at the channel joint 110. In operation, a first aqueous fluid 112 including suspended cells 114 can be conveyed along the channel segment 102 to the connector 110, while a second fluid 116 that is immiscible with the aqueous fluid 112 is delivered from the channel segments 104 and 106 to the connector 110 to form discrete droplets 118 of the aqueous fluid including single cells 114, which flow into the channel segment 108.
[0074] In some aspects, this second fluid 116 comprises an oil, such as a fluorinated oil, which includes a fluorosurfactant for stabilizing the resulting droplets (e.g., inhibiting subsequent coalescence of the resulting droplets). Examples of particularly suitable dispensing fluids and fluorosurfactants are described, for example, in U.S. Patent Publication No. 2010 / 0105112, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes.
[0075] In other aspects, in addition to or as an alternative to droplet-based distribution, cells can be encapsulated in a microcapsule comprising a shell or layer or porous matrix in which one or more single cells or small cell groups are entrained, and other reagents may be included. Cell encapsulation can be performed by a variety of methods. In general, such methods combine an aqueous fluid containing cells to be analyzed with a polymer precursor material that can be formed into a gel or other solid or semi-solid matrix after applying a specific stimulus to the polymer precursor. Such stimuli include, for example, thermal stimuli (heating or cooling), light stimuli (e.g., by photocuring), chemical stimuli (e.g., by crosslinking the precursor, initiating polymerization of the precursor (e.g., by an added initiator), etc.
[0076] Preparation of microcapsules containing cells can be performed by a variety of methods. For example, an air knife droplet or aerosol generator can be used to dispense droplets of a precursor fluid into a gelling solution to form microcapsules including single cells or small groups of cells. Likewise, a membrane-based encapsulation system (such as those available from, for example, Nanomi, Inc.) can be used to produce the microcapsules described herein. In some aspects, such as Figure 1 The microfluidic system shown in can be readily used to encapsulate the cells described herein. In particular, and with reference to Figure 1 , an aqueous fluid containing cells and polymer precursor materials is caused to flow into a channel connector 110, where it is distributed into droplets 118 containing single cells 114 by the flow of a non-aqueous fluid 116. In the case of an encapsulation method, the non-aqueous fluid 116 may also include an initiator to cause polymerization and / or cross-linking of the polymer precursor to form microcapsules including entrained cells. Examples of particularly suitable polymer precursor / initiator pairs include those described in, for example, U.S. Patent Application Nos. 61 / 940,318 filed on February 7, 2014, 61 / 991,018 filed on May 9, 2014, and 14 / 316,383 filed on June 26, 2014, the entire disclosures of which are incorporated herein by reference in their entirety for all purposes.
[0077] For example, where the polymer precursor material comprises a linear polymer material (e.g., linear polyacrylamide, PEG, or other linear polymeric material), the activator may comprise a crosslinker or a chemical that activates the crosslinker within the formed droplets. Likewise, for polymer precursors comprising polymerizable monomers, the activator may comprise a polymerization initiator. For example, in some cases, where the polymer precursor comprises a mixture of acrylamide monomer and N,N'-bis-(acryloyl)cystamine (BAC) comonomer, a reagent such as tetraethylmethylenediamine (TEMED) may be provided within the second fluid stream in channel segments 104 and 106, which initiates copolymerization of acrylamide and BAC into a crosslinked polymer network or hydrogel.
[0078] After the second fluid stream 116 contacts the first fluid stream 112 at the joint 110 in the formation of the droplets, TEMED can diffuse from the second fluid 116 into the aqueous first fluid 112 containing linear polyacrylamide, which will activate the cross-linking of the polyacrylamide within the droplets, thereby causing the formation of gel (e.g., hydrogel) microcapsules 118 as solid or semi-solid beads or particles sandwich cells 114. Although described with respect to polyacrylamide encapsulation, other 'activatable' encapsulation compositions can also be employed in the context of the methods and compositions described herein. For example, the formation of alginate droplets followed by exposure to divalent metal ions, such as Ca2+, can be used as an encapsulation process using the described methods. Similarly, agarose droplets can also be converted into capsules by gelation based on temperature (e.g., after cooling, etc.). As should be understood, in some cases, encapsulated cells can be selectively released from microcapsules, such as by the passage of time or after the application of a specific stimulus, which causes the microcapsules to degrade sufficiently to allow cells or their contents to be released from the microcapsules, such as into additional partitions (such as droplets). For example, in the case of the polyacrylamide polymer described above, degradation of the microcapsules can be achieved by introducing an appropriate reducing agent (such as DTT, etc.) to cleave the disulfide bonds of the cross-linked polymer matrix (see, e.g., U.S. Provisional Patent Application No. 61 / 940,318, filed February 7, 2014, U.S. Provisional Patent Application No. 61 / 991,018, filed May 9, 2014, and U.S. Patent Application No. 14 / 316,383, filed June 26, 2014, the entire disclosures of which are incorporated herein by reference in their entirety for all purposes.
[0079] As should be understood, encapsulated cells or cell colonies provide some potential advantages that can be stored and more portable than cells distributed based on droplets. In addition, in some cases, it may be necessary to allow the cells to be analyzed to hatch for a selected period of time, to characterize the changes of such cells over time in the presence or absence of different stimuli. In such cases, the encapsulation of a single cell can allow a longer incubation than simply distributing in an emulsion droplet, but in some cases, the cells distributed by droplets can also be incubated for different times, such as at least 10 seconds, at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours or at least 10 hours or more. As mentioned above, the encapsulation of cells can constitute the distribution of cells to which other reagents are distributed in total. Alternatively, encapsulated cells can be easily deposited in other partitions (such as droplets) as described above.
[0080] According to some aspects, cells can be distributed together with lytic reagents to release the contents of cells in partitions. In such cases, cells can be introduced into the distribution joint / droplet generation zone, for example, by channels upstream of additional channels or channel joints 110, or when cells are about to be introduced into the distribution joint / droplet generation zone, the lytic agent is contacted with the cell suspension. Examples of lytic agents include bioactive agents, such as lytic enzymes for dissolving different cell types (e.g., gram positive or negative bacteria, plants, yeast, mammals, etc.), such as lysozymes, colorless peptidases, lysostaphin, labiase, thioglucosidase white mustard (kitalase), lytic enzymes (lyticase), and various other lytic enzymes that can be obtained from, for example, Sigma-Aldrich, Inc. (St Louis, MO), and other commercially available lytic enzymes. Other lytic agents can be distributed with cells in addition or alternatively so that the contents of the cells are released into partitions. For example, in some cases, a surfactant-based lysis solution can be used to lyse cells, although these may be less desirable for emulsion-based systems, where surfactants can interfere with stable emulsions. In some cases, the lysis solution may include a nonionic surfactant, such as Triton X-100 and Tween 20. In some cases, the lysis solution may include an ionic surfactant, such as sodium lauryl sarcosinate and sodium dodecyl sulfate (SDS). Similarly, in some cases, a lysis method using other methods that can be used (such as electroporation, heat, sound or mechanical cell disruption) can also be used, such as non-emulsion-based distribution, such as cell encapsulation that can be used in addition to or in place of droplet distribution, wherein any pore size of the encapsulation is small enough to retain nucleic acid fragments of the desired size after cell disruption.
[0081] In addition to the above-described lysing agents co-assigned with cells, other reagents may also be co-assigned with cells, including, for example, DNA enzyme and RNA enzyme inactivators or inhibitors, such as proteinase K; Chelating agents, such as EDTA; And other reagents for removing or otherwise reducing the negative activity or effects of subsequent treatment of nucleic acids by different cell lysate components. In addition, in the case of encapsulated cells, cells may be exposed to appropriate stimulation to release cells or their contents from co-assigned microcapsules. For example, in some cases, chemical stimulation may be co-assigned with encapsulated cells to allow microcapsule degradation and release of cells or their contents into larger partitions. In some cases, this stimulation may be the same as described elsewhere herein for releasing oligonucleotides from their respective beads or partitions. In alternative aspects, this stimulation may be different and non-overlapping stimulations to allow encapsulated cells to be released into the same partition at a different time from the oligonucleotides being released into the partition.
[0082] Additional reagents can be co-assigned with cells, such as endonucleases for fragmenting the DNA of cells, nucleic acid fragments for amplifying cells, and DNA polymerases and dNTPs for connecting barcode oligonucleotides to amplified fragments. Additional reagents can also include reverse transcriptases (including enzymes with terminal transferase activity), primers and oligonucleotides, and conversion oligonucleotides (also referred to herein as "conversion oligos") that can be used for template switching. In some cases, template switching can be used to increase the length of cDNA. In an example of template switching, cDNA can be produced by reverse transcription of a template (e.g., cell mRNA), wherein a reverse transcriptase with terminal transferase activity can add additional nucleotides (e.g., polycytidylic acid) such as at the end of cDNA to a cDNA not encoded by a template. Conversion oligonucleotides can include sequences complementary to additional nucleotides (e.g., polyguanylic acid). Additional nucleotides on cDNA (e.g., polycytidylic acid) can hybridize with sequences complementary to additional nucleotides on conversion oligonucleotides (e.g., polyguanylic acid), whereby conversion oligonucleotides can be used as templates by reverse transcriptase to further extend cDNA. The conversion oligonucleotide may be composed of DNA, RNA, modified nucleic acid (including locked nucleic acid (LNA)), or any combination.
[0083] In some cases, the length of the conversion oligonucleotide can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 ,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,1 38, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195 5, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 nucleotides or longer.
[0084] In some cases, the length of the conversion oligonucleotide can be at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 4, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 1 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, or 250 nucleotides or longer.
[0085] 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137 , 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194 , 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides.
[0086] Once the contents of the cell are released into their respective partitions, the nucleic acids contained therein can be further processed in the partitions. According to the methods and systems described herein, a unique identifier is generally provided for the nucleic acid contents of a single cell, so that after characterizing those nucleic acids, they can be attributed to the same cell. The ability to attribute features to a single cell or a cell group is provided by specifically assigning a unique identifier to a single cell or a cell group, which is another advantageous aspect of the methods and systems described herein. Specifically, a unique identifier such as a nucleic acid barcode is assigned or associated with a single cell or a cell group to tag (tag / label) the components of the cell (and therefore, mark its features) with a unique identifier. These unique identifiers are then used to attribute the components and features of the cell to a single cell or a cell group. In some aspects, this is performed by co-assigning a single cell or a cell group with a unique identifier. In some aspects, a unique identifier is provided in the form of an oligonucleotide comprising a nucleic acid barcode sequence, which can be connected to or otherwise associated with the nucleic acid contents of a single cell, or connected to other components of the cell, and particularly to fragments of those nucleic acids. Oligonucleotides are distributed so that the nucleic acid barcode sequences contained therein are identical between oligonucleotides in a given partition, but oligonucleotides can and do have different barcode sequences between different partitions, or at least a large number of different barcode sequences are present in all partitions in a given analysis. In some aspects, only one nucleic acid barcode sequence can be associated with a given partition, although in some cases, two or more different barcode sequences can be present.
[0087] The nucleic acid barcode sequence may include 6 to about 20 or more nucleotides in the sequence of the oligonucleotide. In some cases, the length of the barcode sequence may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of the barcode sequence may be at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of the barcode sequence may be at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or shorter. These nucleotides may be completely continuous, i.e., in the form of a single segment of adjacent nucleotides, or they may be separated into two or more separate subsequences separated by one or more nucleotides. In some cases, the length of the separated barcode subsequences can be about 4 to about 16 nucleotides. In some cases, the barcode subsequences can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequences can be at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequences can be at most 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or shorter.
[0088] The co-assigned oligonucleotides may also include other functional sequences suitable for processing nucleic acids from co-assigned cells. These sequences include, for example, targeted or random / universal amplification primer sequences, which are used to amplify the genomic DNA of individual cells within the partition while connecting to the associated barcode sequence; sequencing primers or primer recognition sites, hybridization or detection sequences, such as for identifying the presence of a sequence or for pulling down barcoded nucleic acids; or any of many other potential functional sequences. Again, the co-assignment of oligonucleotides and associated barcodes and other functional sequences together with sample materials is described in, for example, U.S. Patent Application No. 61 / 940,318 filed on February 7, 2014 and U.S. Patent Application No. 61 / 991,018 filed on May 9, 2014 and U.S. Patent Application No. 14 / 316,383 filed on June 26, 2014 and U.S. Patent Application No. 14 / 175,935 filed on February 7, 2014, which have been previously incorporated herein by reference. As will be appreciated, other mechanisms for co-partitioning oligonucleotides may also be employed, including, for example, coalescence of two or more droplets, one of which contains an oligonucleotide, or micropartitioning of oligonucleotides into partitions, such as droplets within a microfluidic system.
[0089] Briefly, in one example, beads, microparticles or microcapsules are provided, each comprising a plurality of oligonucleotides as described above releasably attached to the beads, wherein all oligonucleotides attached to a particular bead will comprise the same nucleic acid barcode sequence, but wherein a large variety of barcode sequences may be present in the population of beads used. In particularly useful examples, hydrogel beads, for example comprising a polyacrylamide polymer matrix, are used as solid supports and delivery vehicles for oligonucleotide access partitions, as they are capable of carrying a large number of oligonucleotide molecules, and can be configured to release those oligonucleotides upon exposure to a specific stimulus as described elsewhere herein. In some cases, the bead population will provide a diverse library of barcode sequences including at least 1,000 different barcode sequences, at least 5,000 different barcode sequences, at least 10,000 different barcode sequences, at least at least 50,000 different barcode sequences, at least 100,000 different barcode sequences, at least 1,000,000 different barcode sequences, at least 5,000,000 different barcode sequences, or at least 10,000,000 different barcode sequences. Additionally, each bead can have a large number of attached oligonucleotide molecules. In particular, the number of oligonucleotide molecules comprising a barcode sequence on a single bead can be at least 1,000 oligonucleotide molecules, at least 5,000 oligonucleotide molecules, at least 10,000 oligonucleotide molecules, at least 50,000 oligonucleotide molecules, at least 100,000 oligonucleotide molecules, at least 500,000 oligonucleotides, at least 1,000,000 oligonucleotide molecules, at least 5,000,000 oligonucleotide molecules, at least 10,000,000 oligonucleotide molecules, at least 50,000,000 oligonucleotide molecules, at least 100,000,000 oligonucleotide molecules, and in some cases at least 1 billion oligonucleotide molecules.
[0090] In addition, when the bead population is partitioned, the resulting partitioned population can also include a diverse barcode library comprising at least 1,000 different barcode sequences, at least 5,000 different barcode sequences, at least 10,000 different barcode sequences, at least at least 50,000 different barcode sequences, at least 100,000 different barcode sequences, at least 1,000,000 different barcode sequences, at least 5,000,000 different barcode sequences, or at least 10,000,000 different barcode sequences. Additionally, individual partitions of a population may include at least 1,000 oligonucleotide molecules, at least 5,000 oligonucleotide molecules, at least 10,000 oligonucleotide molecules, at least 50,000 oligonucleotide molecules, at least 100,000 oligonucleotide molecules, at least 500,000 oligonucleotides, at least 1,000,000 oligonucleotide molecules, at least 5,000,000 oligonucleotide molecules, at least 10,000,000 oligonucleotide molecules, at least 50,000,000 oligonucleotide molecules, at least 100,000,000 oligonucleotide molecules, and in some cases at least 1 billion oligonucleotide molecules.
[0091] In some cases, it may be desirable to incorporate multiple different barcodes within a given partition, attached to a single or multiple beads within the partition. For example, in some cases, a mixed but known set of barcode sequences can provide greater assurance of identification in subsequent processing, such as by providing stronger addressing or attribution of a barcode to a given partition as a duplicate or independent confirmation of output for a given partition.
[0092] Oligonucleotide can be released from beads after specific stimulation is applied to beads. In some cases, stimulation can be light stimulation, such as by releasing the cracking of the light instability bond of oligonucleotide. In other cases, thermal stimulation can be used, wherein the temperature increase of bead environment may cause the cracking of bond or other releases of oligonucleotide from beads. In other cases, chemical stimulation is used, which cracks the bond of oligonucleotide and beads, or otherwise causes oligonucleotide to be released from beads. The example of this type of system is described in U.S. Patent Application No. 13 / 966,150 filed on August 13, 2013 and U.S. Provisional Patent Application No. 61 / 940,318 filed on February 7, 2014, U.S. Provisional Patent Application No. 61 / 991,018 filed on May 9, 2014 and U.S. Patent Application No. 14 / 316,383 filed on June 26, 2014, the entire disclosure of the patent application is incorporated herein by reference in its entirety for all purposes. In one instance, such a composition comprises a polyacrylamide matrix as described above for cell encapsulation, and can be degraded by exposure to a reducing agent (such as DTT) to release the attached oligonucleotides.
[0093] According to the methods and systems described herein, beads including attached oligonucleotides are co-distributed with single cells so that a single partition contains a single bead and a single cell. As mentioned above, when single cell / single bead occupancy is the most desired state, it should be understood that there will often be multiple occupied partitions (in terms of cells, beads, or both), or unoccupied partitions (in terms of cells, beads, or both). Figure 2 In the example of the microfluidic channel structure for co-distributing cells and beads comprising barcode oligonucleotides is schematically illustrated.As described elsewhere herein, in some aspects, a considerable percentage will include beads and cells in all occupied subregions, and in some cases, some of the produced subregions will be unoccupied.In some cases, some of the subregions may have beads and cells that are not distributed in 1:1.In some cases, it may be necessary to provide multiple occupied subregions, such as containing two, three, four or more cells and / or beads in a single subregion.As shown in the figure, channel sections 202, 204, 206, 208 and 210 are provided in the form of fluid communication at channel joint 212.The aqueous stream 214 comprising a single cell is made to flow to channel joint 212 by channel section 202.As described above, these cells can be suspended in aqueous fluids, or can be pre-packaged before the distribution process.
[0094] At the same time, an aqueous stream 216 containing barcode-bearing beads is caused to flow through the channel segment 204 toward the channel junction 212. A non-aqueous dispensing fluid 216 is introduced into the channel junction 212 from each of the side channels 206 and 208, and the combined stream is caused to flow into the outlet channel 210. Within the channel junction 212, the two combined aqueous streams from the channel segments 202 and 204 are combined together and dispensed into droplets 218, which include the co-dispensed cells 214 and beads 216. As previously mentioned, by controlling the flow characteristics of each of the fluids combined at the channel junction 212 and controlling the geometry of the channel junction, the combination and dispensing can be optimized to achieve a desired occupancy level of beads, cells, or both within the resulting partitions 218.
[0095] In some cases, a dissolving agent (e.g., a lytic enzyme) can be introduced into a partition together with a bead stream, such as flowing through a channel section 204, so that the dissolution of the cell only begins when or after the distribution. Additional reagents can also be added to the partition in this configuration, such as an endonuclease for the DNA fragmentation of the cell, a nucleic acid fragment for amplifying the cell, and a DNA polymerase and dNTP for connecting the barcode oligonucleotide to the amplified fragment. As mentioned above, in many cases, a chemical stimulus (such as DTT) can be used to release the barcode from its respective beads into the partition. In such cases, it may be particularly desirable to provide the chemical stimulus in the channel section 202 together with the cell-containing stream so that the release of the barcode occurs only after the two streams have been combined in, for example, a partition 218. However, in the case where cells are encapsulated, for example, the introduction of a common chemical stimulus that releases oligonucleotides from its beads and releases cells from its microcapsules can generally be provided from a separate additional side channel (not shown) upstream of the channel connector 212 or connected to the channel connector 212.
[0096] As will be appreciated, a number of other reagents may be co-dispensed with the cells, beads, lysis agents, and chemical stimuli, including, for example, protecting reagents, such as proteinase K; chelating agents; nucleic acid extension, replication, transcription or amplification reagents, such as polymerases, reverse transcriptases, transposases useful in transposon-based methods (e.g., Nextera), nucleoside triphosphate or NTP analogs, primer sequences, and additional cofactors (such as divalent metal ions for use in such reactions), ligation reaction reagents (such as ligases and ligation sequences); dyes, labels, or other labeling reagents.
[0097] For example, the channel network as described herein can be fluidly coupled to an appropriate fluid component. For example, the inlet channel segment (e.g., channel segment 202, 204, 206, and 208) is fluidly coupled to the appropriate source of materials that they are to be delivered to the channel joint 212. For example, channel segment 202 couples the fluid to the source of the cell aqueous suspension 214 to be analyzed, and channel segment 204 couples the fluid to the source of the bead aqueous suspension 216. Then, channel segments 206 and 208 are fluidly connected to one or more sources of non-aqueous fluids. These sources can include any of a variety of different fluid components such as a simple reservoir defined in or connected to the main structure of the microfluidic device to a fluid conduit for delivering fluids from an external source, a manifold of the device. Similarly, the outlet channel segment 210 can be fluidly coupled to a receiving container or conduit of the cells distributed. Again, this may be a reservoir defined in the body of the microfluidic device, or it may be a fluid conduit used to deliver the dispensed cells to subsequent processing operations, instruments or components.
[0098] Figure 8An image of a single Jurkat cell co-dispensed with beads containing barcode oligonucleotides in an aqueous droplet in a water-in-oil emulsion is shown. As shown, a single cell can be easily co-dispensed with a single bead. As will be appreciated, optimization of single cell loading can be performed by a number of methods, including by providing a dilution of a cell population into a microfluidic system to achieve the desired cell loading for each partition as described elsewhere herein.
[0099] In operation, once dissolved, the nucleic acid content of a single cell can then be used for further processing in a partition, including, for example, fragmentation, amplification and barcoding, and the connection of other functional sequences. As mentioned above, fragmentation can be achieved by the co-distribution of a shearing enzyme (such as an endonuclease), so that nucleic acid fragmentation is smaller. These endonucleases can include restriction endonucleases, including II type and IIs type restriction endonucleases and other nucleic acid lysing enzymes, such as nicking endonucleases, etc. In some cases, fragmentation may not be needed, and full-length nucleic acids can be retained in a partition, or in the case of encapsulated cells or cell contents, fragmentation can be carried out before distribution, for example, by enzymatic methods (such as those described herein) or by mechanical methods (such as machinery, acoustics or other shearing).
[0100] Once co-distributed and cells are dissolved to release their nucleic acids, the oligonucleotides disposed on the beads can be used to barcode and amplify fragments of those nucleic acids. A particularly simple method of using these barcode oligonucleotides when amplifying and barcoding fragments of sample nucleic acids is described in detail in U.S. Provisional Patent Application No. 61 / 940,318 filed on February 7, 2014, 61 / 991,018 filed on May 9, 2014, and U.S. Patent Application No. 14 / 316,383 filed on June 26, 2014 and previously incorporated by reference. Briefly, in one aspect, the oligonucleotides present on the beads co-distributed with the cells are released from their beads into the partitions together with the nucleic acids of the cells. The oligonucleotides can include a primer sequence at its 5' end (together with the barcode sequence). This primer sequence can be a random oligonucleotide sequence intended to randomly guide many different regions of the nucleic acid of the cell or it can be a specific primer sequence that targets the upstream of a specific targeted region of the genome of the guiding cell.
[0101] Once released, the primer portion of the oligonucleotide can anneal with the complementary region of the nucleic acid of the cell. The extension reaction reagent (e.g., DNA polymerase, nucleoside triphosphate, cofactor (e.g., Mg2+ or Mn2+)) also distributed with the cell and the beads then uses the nucleic acid of the cell as a template to extend the primer sequence to produce a complementary fragment of the chain of the nucleic acid of the cell annealed with the primer, the complementary fragment comprising the oligonucleotide and its associated barcode sequence. The annealing and extension of multiple primers to different parts of the nucleic acid of the cell will produce a large collection of overlapping complementary fragments of nucleic acid, each of which has its own barcode sequence indicating the partition in which it is formed. In some cases, these complementary fragments themselves can be used as templates, and the template is guided by the oligonucleotide present in the partition to produce a complementary sequence of the complementary sequence, which in turn includes a barcode sequence. In some cases, this replication process is configured so that when the first complementary sequence is repeated, it produces two complementary sequences located at or near its end to allow the formation of a hairpin structure or a partial hairpin structure, thereby reducing the ability of the molecule to become the basis for producing other repeated copies. As described herein, the nucleic acid of a cell may include any desired nucleic acid within the cell, including, for example, the cell's DNA (e.g., genomic DNA), RNA (e.g., messenger RNA), etc. For example, in some cases, the methods and systems described herein are used to characterize the expressed mRNA, including, for example, the presence and quantification of such mRNA, and may include RNA sequencing methods as characterization methods. Alternatively or additionally, reagents distributed with the cell may include reagents for converting mRNA into cDNA, such as reverse transcriptase; and reagents for facilitating sequencing methods using DNA sequencing. In some cases, where the nucleic acid to be characterized includes RNA, such as mRNA, Figure 3 A schematic illustration of an example of this situation is shown in .
[0102] As shown, an oligonucleotide including a barcode sequence is co-dispensed with sample nucleic acid 304 in a droplet 302, such as in an emulsion. As mentioned elsewhere herein, as shown in Figure A, an oligonucleotide 308 may be provided on a bead 306 co-dispensed with sample nucleic acid 304, from which the oligonucleotide may be released. Oligonucleotide 308 includes a barcode sequence 312 in addition to one or more functional sequences, such as sequences 310, 314, and 316. For example, oligonucleotide 308 is shown as including a barcode sequence 312 and a sequence 310 that may serve as a linker or anchor sequence for a given sequencing system, such as for use in an Illumina sequencing system. or In the example of the present invention, oligonucleotide 308 is a nucleic acid sequence of the present invention, wherein the oligonucleotide comprises a primer sequence 316, which may include a random or targeted N-mer for guiding the replication of several parts of the sample nucleic acid 304. Oligonucleotide 308 also includes a sequence 314, which may provide a sequencing guide region, such as "read segment 1" or an R1 guide region, which is used to guide the polymerase-mediated template directional sequencing by the synthesis reaction in the sequencing system. As should be understood, the functional sequence can be selected to be compatible with a variety of different sequencing systems (such as 454 sequencing, Ion Torrent Proton or PGM, Illumina X10, etc.) and its requirements. In many cases, barcode sequence 312, fixed sequence 310 and R1 sequence 314 may be common for all oligonucleotides connected to a given bead. Primer sequence 316 may be different due to random N-mer primers, or may be common for the oligonucleotides on a given bead in some targeted applications.
[0103] As will be appreciated, in some cases, the functional sequence may include primer sequences suitable for RNA-seq applications. For example, in some cases, the oligonucleotides may include polythymidylate primers for guiding reverse transcription of RNA for RNA-seq. In other cases, the oligonucleotides included in a given partition, for example, on a single bead, may include multiple types of primer sequences in addition to a common barcode sequence, such as DNA-sequencing and RNA-sequencing primers, such as polythymidylate primer sequences included in the oligonucleotides coupled to the beads. In such cases, DNA and RNA sequencing processes may be performed on a single partitioned cell.
[0104] Based on the presence of primer sequence 316, the oligonucleotides can prime the sample nucleic acid as shown in Figure B, which allows the use of polymerases and other extension reagents that are also co-distributed with beads 306 and sample nucleic acid 304 to extend oligonucleotides 308 and 308a. As shown in Figure C, after the oligonucleotides that anneal to multiple different regions of sample nucleic acid 304 for random N-mer primers are extended; multiple overlapping complementary sequences or fragments of nucleic acid are formed, such as fragments 318 and 320. Although sequence portions that are complementary to several portions of the sample nucleic acid are included, such as sequences 322 and 324, these constructs are generally referred to herein as fragments comprising sample nucleic acid 304 with attached barcode sequences.
[0105] The barcoded nucleic acid fragments can then be characterized, for example, by sequence analysis, or can be further amplified as in the process shown in FIG. For example, additional oligonucleotides (e.g., oligonucleotide 308b) also released from bead 306 can guide fragments 318 and 320. This is shown for fragment 318. Specifically, again, based on the presence of random N-mer primer 316b in oligonucleotide 308b (which in many cases may be different from other random N-mers in a given partition, such as primer sequence 316), the oligonucleotide anneals with fragment 318 and extends to form a complementary sequence 326 of at least a portion of sequence 328 in fragment 318, which comprises a repeat of a portion of the sample nucleic acid sequence. Oligonucleotide 308b continues to extend until it has been replicated by the oligonucleotide portion 308 of fragment 318. As mentioned elsewhere herein, and as illustrated in FIG. D, the oligonucleotide can be configured to prompt the replication by the polymerase to stop at a desired point, such as after replication by sequences 316 and >314 included in fragment 18 of the oligonucleotide 308. As described herein, this can be achieved by different methods, including, for example, incorporating different nucleotides and / or nucleotide analogs that cannot be processed by the polymerase used. For example, this can include incorporating uracil-containing nucleotides in the sequence region 312 to prevent non-uracil tolerant polymerases from stopping the replication of the region. As a result, a fragment 326 is formed, which includes a full-length oligonucleotide 308b at one end, including a barcode sequence 312, a linker sequence 310, an R1 primer region 314, and a random N-mer sequence 316b. At the other end of the sequence, a complementary sequence 316' of the random N-mer of the first oligonucleotide 308 and a complementary sequence of the entire or a portion of the R1 sequence (shown as sequence 314') can be included. The R1 sequence 314 and its complementary sequence 314' can then hybridize together to form a partial hairpin structure 328. As will be appreciated, because the random N-mers between different oligonucleotides are different, these sequences and their complementary sequences are not expected to participate in hairpin formation, for example, sequence 316' (which is the complementary sequence of random N-mer 316) is not expected to be complementary to random N-mer sequence 316b. This will not be the case for other applications, such as targeted primers, where the N-mers between oligonucleotides within a given partition will be common.
[0106] By forming these partial hairpin structures, the first order repeats of the sample sequence are allowed to be removed from further replication, thereby, for example, preventing repeated copies of copies. The partial hairpin structures also provide a useful structure for subsequent processing of the formed fragments (eg, fragment 326).
[0107] Generally, amplification of nucleic acid from the cell is performed until the barcoded overlapping fragments within the partitions provide at least 1X coverage of a particular portion or all of the cell's genome, at least 2X, at least 3X, at least 4X, at least 5X, at least 10X, at least 20X, at least 40X, or more coverage of the genome or a relevant portion thereof of interest. Once the barcoded fragments are generated, they can be sequenced on an appropriate sequencing system (e.g., Illumina It can be sequenced directly on a PCR or X10 system), or it can be additionally processed, such as further amplified, connected to other functional sequences (e.g., a second sequencing primer (for reverse reads), a sample index sequence, etc.).
[0108] All fragments can then be pooled from multiple different partitions for sequencing on a high-throughput sequencer as described herein, wherein the pooled fragments include a large number of fragments of nucleic acids originating from different cells or smaller cell populations, but wherein the fragments of nucleic acids from a given cell will share the same barcode sequence. Specifically, because each fragment is coded with respect to its partition of origin and therefore its single cell or small cell population, the sequence of the fragment can be attributed back to that cell or cells based on the presence of the barcode, which will also help apply the individual sequence fragments from multiple partitions to the assembly of a single genome of different cells. Figure 4 This is schematically illustrated in FIG. As shown in one example, as described above, a first nucleic acid 404 from a first cell 400 and a second nucleic acid 406 from a second cell 402 are each distributed with their own set of barcode oligonucleotides. The nucleic acid may include a chromosome, an entire genome, or other large nucleic acid from a cell.
[0109] In each partition, the nucleic acid 404 and 406 of each cell is then processed to provide overlapping second fragment sets of the first fragments separately, such as second fragment sets 408 and 410. This processing also provides second fragments, wherein the barcode sequence of each of the second fragments derived from a specific first fragment is the same. As shown, the barcode sequence of the second fragment set 408 is represented by "1", and the barcode sequence of the fragment set 410 is represented by "2". A large number of different fragment sets can be barcoded using a diverse barcode library. However, it is not necessary to barcode each second fragment set from different first fragments with different barcode sequences. In fact, in many cases, multiple different first fragments can be processed simultaneously to include the same barcode sequence. Various barcode libraries are described in detail elsewhere herein.
[0110] The barcoded fragments, e.g., from fragment collections 408 and 410, can then be pooled for sequencing using, e.g., sequence obtained by synthesis technology available from the Illumina or Ion Torrent divisions of Thermo Fisher, Inc. Once sequenced, sequence reads 412 can be attributed to their respective fragment collections based at least in part on the included barcodes and, in some cases, based in part on the sequence of their fragments, e.g., as shown in aggregated reads 414 and 416. The sequence reads attributed to each fragment collection are then assembled to provide an assembled sequence of nucleic acids of each cell, e.g., sequences 418 and 420, which in turn can be attributed to individual cells, e.g., cells 400 and 402.
[0111] Although described with respect to analyzing genetic material present in cells, the methods and systems described herein may have much broader applicability, including the ability to characterize other aspects of individual cells or cell populations by allowing reagents to be dispatched to individual cells and providing dispatchable analysis or characterization of those cells in response to those reagents. These methods and systems are particularly valuable in being able to characterize cells for, for example, research, diagnosis, pathogen identification, and many other reasons. For example, a wide range of different cell surface features (e.g., cell surface proteins, such as differentiation or CD protein clusters) have significant diagnostic relevance in the characterization of diseases such as cancer.
[0112] In one particularly useful application, the methods and systems described herein can be used to characterize cellular features, such as cell surface features, e.g., proteins, receptors, etc. In particular, the methods described herein can be used to attach reporter molecules to these cellular features, which, when distributed as described above, can be barcoded and analyzed, e.g., using DNA sequencing technology, to determine the presence and, in some cases, the relative abundance or amount of such cellular features within a single cell or a population of cells.
[0113] In a specific example, a library of potential cell binding ligands (e.g., antibodies, antibody fragments, cell surface receptor binding molecules, etc.) associated with a first group of nucleic acid reporter molecules can be provided, such as where different reporting oligonucleotide sequences are associated with specific ligands, and are therefore capable of being bound to specific cell surface features. In some aspects, different members of the library can be characterized by the presence of different oligonucleotide sequence markers, such as antibodies to cell surface proteins or receptors of the first type will be associated with its first known reporting oligonucleotide sequence, and antibodies to the second receptor protein will have different known reporting oligonucleotide sequences associated with it. Before co-distribution, cells will be incubated with a ligand library, which can present antibodies to different cell surface features of a wide range, such as receptors, proteins, etc., and it includes the reporting oligonucleotides to which it is associated. Unbound ligands are washed from cells, and then cells are co-distributed with the barcode oligonucleotides described above. Therefore, partitions will include one or more cells and bound ligands and their known associated reporting oligonucleotides.
[0114] Without the need to lyse cells within the partition, the reporter oligonucleotides can then be subjected to the barcoding operations described above for the cellular nucleic acid to produce barcoded reporter oligonucleotides, wherein the presence of the reporter oligonucleotides can indicate the presence of specific cell surface features, and the barcode sequence will allow the range of different cell surface features to be attributed to a given single cell or cell population based on the barcode sequence co-assigned with the cell or cell population. Thus, cell surface feature patterns can be generated cell by cell within a wider cell population. This aspect of the methods and systems described herein is described in more detail below.
[0115] Figure 5 This example is schematically illustrated in Figure 5. As shown in the figure, the cell colony represented by cells 502 and 504 is incubated with a library of cell surface association reagents (such as antibodies, cell surface binding proteins, ligands, etc.), wherein various types of binding bases include ligands and related reporter molecules 506, 508, 510 and 512 (wherein the reporter molecules are indicated by circles of different shadows) The associated nucleic acid reporter molecules associated with it are shown in the form. In the case where the cell expresses the surface features combined by the library, the ligand and its related reporter molecules can become associated or coupled with the cell surface. Then a single cell is assigned to a separate partition (such as droplet 514 and 516) with its related ligand / reporter molecules and a single barcode oligonucleotide bead (such as bead 522 and 524) as described elsewhere herein. As in the case of other examples described herein, barcoded oligonucleotides are released from beads, and used to connect the barcode sequence to the reporter molecules present in each partition, wherein the barcode of a given partition is common, but the barcodes between different partitions are greatly different. For example, if Figure 5As shown in , the reporter molecules associated with cells 502 in partition 514 are barcoded with barcode sequence 518, while the reporter molecules associated with cells 504 in partition 516 are barcoded with barcode 520. Thus, there is a library of oligonucleotides that reflect the surface ligands of the cells as reflected by the reporter molecules, but which are generally attributable to a single cell by virtue of a common barcode sequence, thereby allowing single cell level profiling of the surface characteristics of the cells. As will be appreciated, this approach is not limited to cell surface receptors, but can be used to identify the presence of a variety of specific cell structures, chemicals or other characteristics.
[0116] III. Applications of Single Cell Analysis
[0117] The single cell processing and analysis methods and systems described herein have a variety of different applications, including analysis of specific single cells for environmental, human health, epidemiological forensics, or any of a variety of different applications, analysis of different cell types within a population of different cell types, analysis and characterization of larger cell populations.
[0118] One particularly valuable application of the single cell analysis methods described herein is sequencing and characterizing cancer cells. In particular, conventional analysis techniques (including the bulk sequencing methods mentioned above) are very poor at picking out smaller variations in the genomic makeup of cancer cells, especially when those changes are present in a large number of normal tissue cells. Furthermore, even among tumor cells, large variations can exist and can be masked by the overall method used for sequencing (see, e.g., Patel et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science DOI: 10.1126 / science.1254257 (published online June 12, 2014). Cancer cells can be derived from solid tumors, hematological malignancy cell lines, or obtained as circulating tumor cells and subjected to the partitioning process described above. When analyzed, single cell sequences can be identified as originating from a single cell or a small group of cells and distinguished from normal tissue cell sequences. In addition, phased sequence information can also be obtained from each cell, as described in co-pending U.S. Provisional Patent Application No. 62 / 017,808, filed June 26, 2014, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes. Single cell analysis methods are particularly suitable for systems and methods involving low input nucleic acid amounts, as described in co-pending U.S. Provisional Patent Application No. 62 / 017,580, filed on June 26, 2014, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes.
[0119] As in the case of cancer cell analysis, using conventional techniques to analyze fetal health or abnormal analysis and diagnosis by fetal cell is a difficult task. Specifically, in the absence of relatively invasive procedures, amniocentesis such as obtaining fetal cell samples can be used to harvest those cells from the maternal circulation. As should be understood, such circulating fetal cells constitute a very small part in the entire cell population of the circulation. Therefore, a complex analysis is performed to characterize what may be derived from fetal cells rather than maternal cells in the obtained data. However, by adopting the single cell characterization method and system described herein, gene composition can be attributed to a single cell, and those cells are classified as maternal or fetus based on their respective gene composition. In addition, the gene sequence of fetal cells can be used to identify any of many genetic disorders, including, for example, aneuploidy, such as Down syndrome (Down syndrome), Edwards syndrome (Edwards syndrome) and Patau syndrome (Patau syndrome).
[0120] The ability to characterize individual cells from a larger, diverse population of cells is also of significant value in environmental testing and forensic analysis, where a sample may be composed, by its very nature, of a diverse population of cells and other materials that "contaminate" the sample relative to the cells being tested in the sample (e.g., environmental indicator organisms, toxic organisms, etc. for, e.g., environmental and food safety testing; victim and / or perpetrator cells in forensic analysis of sexual assault and other violent crimes; etc.).
[0121] Additional applicable applications of the single cell sequencing and characterization methods described above are in the field of neuroscience research and diagnosis. In particular, neural cells may include long interspersed nuclear elements (LINEs) or 'jumping' genes that can move around in the genome, which makes each neuron different from its neighboring cells. Studies have shown that the number of LINEs in the human brain exceeds that of other tissues, such as heart and liver tissues, and has between 80 and 300 unique insertions (see, e.g., Coufal, NG, et al. Nature 460, 1127–1131 (2009)). These differences have been postulated to be related to the sensitivity of people to neurological disorders (see, e.g., Muotri, AR, et al. Nature 468, 443–446 (2010)), or to provide diversity for the brain to respond to stimulation. Therefore, the methods described herein can be used to sequence and characterize single neural cells.
[0122] As mentioned above, the single cell analysis method described herein is also applicable to the analysis of gene expression in terms of the identification and quantification of RNA transcripts. Specifically, using the single cell level analysis method described herein, RNA transcripts present in a single cell, a cell population, or a subset of a cell population can be separated and analyzed. Specifically, in some cases, the barcode oligonucleotide can be configured to guide, replicate RNA from a single cell and thus generate its barcoded fragments. For example, in some cases, the barcode oligonucleotide may include an mRNA-specific guide sequence, such as a polythymidylate primer segment or other targeted guide sequence that allows guiding and replicating mRNA in a reverse transcription reaction. Alternatively or in addition, random RNA guidance can be performed using a random N-mer primer segment of a barcode oligonucleotide.
[0123] Figure 6 A schematic diagram of an exemplary method for performing RNA expression analysis in a single cell using the method described herein is provided. As shown, at operation 602, live cell sorting is performed to a sample containing cells, which is quantified and diluted for subsequent distribution. At operation 604, single cells are individually co-distributed with gel beads with barcoded oligonucleotides as described herein. At operation 606, the cells are dissolved, and the barcoded oligonucleotides are released into the partition, wherein at operation 608, they react with the mRNA and hybridize with the mRNA, for example, by means of a polythymidylic acid primer sequence complementary to the polyadenylic acid tail of the mRNA. Using the polythymidylic acid barcode oligonucleotide as a guide sequence, reverse transcription reaction is performed at operation 610 to synthesize the cDNA transcript of mRNA, which includes a barcode sequence. Then at operation 612, for example, a PCR method is used to make the cDNA transcript of barcoding additionally amplified, and purification is performed at operation 614, and then it is placed on a nucleic acid sequencing system to measure the cDNA sequence and its associated barcode sequence. In some cases, as shown, operations 602 to 608 can be performed while the reagents remain in their original droplets or partitions, while operations 612 to 616 can be performed in the main body (e.g., outside the partition). In the case where the partition is a droplet in an emulsion, the emulsion can be destroyed and the contents of the droplets can be collected to complete operations 612 to 616. In some cases, the barcode oligonucleotide can be digested with an exonuclease after the emulsion is destroyed. Exonuclease activity can be initiated by ethylenediaminetetraacetic acid (EDTA) after primer digestion. In some cases, operation 610 can be performed based on the co-distribution of a reverse transcription mixture (e.g., reverse transcriptase and related reagents) within a partition, or it can be performed in the main body.
[0124] As mentioned elsewhere herein, the structure of a barcode oligonucleotide can include a number of sequence elements in addition to the oligonucleotide barcode sequence. Figure 7, barcode oligonucleotides are shown for an example in RNA analysis as described above. As shown, the entire oligonucleotide 702 is coupled to beads 704 by releasable linkage 706 (such as disulfide joints). Oligonucleotides may include functional sequences for subsequent processing, such as functional sequences 708, which may include one or more of sequencer-specific flow cell connection sequences (such as P5 sequences for Illumina sequencing systems) and sequencing primer sequences (such as R1 primers for Illumina sequencing systems). Barcode sequences 710 are included in the structure for barcoded sample RNA. mRNA-specific guide sequences (such as polythymidylic acid sequences 712) are also included in the oligonucleotide structure. An anchor sequence segment 714 may be included to ensure that the polythymidylic acid sequence hybridizes at the sequence ends of mRNA. This anchor sequence may include a random short sequence of nucleotides, such as 1-mer, 2-mer, 3-mer or longer sequences, which will ensure that the polythymidylic acid segment is more likely to hybridize at the sequence ends of the polyadenylic acid tails of mRNA. Additional sequence segments 716 may be provided within the oligonucleotide sequence. In some cases, this additional sequence provides a unique molecular sequence segment, for example as a random sequence (e.g., a random N-mer sequence), which is different between single oligonucleotides coupled to a single bead, while the barcode sequence 710 may be constant between oligonucleotides connected to a single bead. This unique sequence is used to provide a unique identifier for the captured starting mRNA molecule to allow the number of RNA initially expressed to be quantified. As will be appreciated, although shown as a single oligonucleotide connected to the bead surface, a single bead may include tens to tens of thousands or even millions of single oligonucleotide molecules, wherein as mentioned, the barcode segment may be constant or relatively constant for a given bead, but wherein the variable or unique sequence segment between single beads will be different. This unique molecular sequence segment may include 5 to about 8 or more nucleotides within the sequence of the oligonucleotide. In some cases, the length of a unique molecular sequence segment may be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides or longer. In some cases, the length of a unique molecular sequence segment may be at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides or longer. In some cases, the length of a unique molecular sequence segment may be at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides or shorter.
[0125] In operation, and with reference to Figure 6 and 7, the cells are co-distributed with the barcoded beads, and dissolved, while the barcoded oligonucleotides are released from the beads. The polythymidylic acid portion of the released barcode oligonucleotides is then hybridized with the polyadenylic acid tail of the mRNA. The polythymidylic acid segment then guides the reverse transcription of the mRNA to produce the cDNA transcript of the mRNA, but it includes each of the sequence segments 708-716 of the barcode oligonucleotides. Again, because the oligonucleotide 702 includes an anchor sequence 714, it will be more likely to hybridize with the polyadenylic acid tail of the mRNA and guide reverse transcription at the sequence end of the polyadenylic acid tail of the mRNA. In any given partition, all cDNA transcripts of a single mRNA molecule will include a common barcode sequence segment 710. However, by including a unique random N-mer sequence, the transcripts obtained by different mRNA molecules in a given partition will be different at this unique sequence. This provides a quantitative feature that can be identified even after any subsequent amplification of the contents of a given partition, for example, the number of unique segments associated with a common barcode can indicate the amount of mRNA derived from a single partition and therefore from a single cell. As mentioned above, the transcripts are then amplified, cleaned up and sequenced to identify the sequence of the cDNA transcript of the mRNA, and the barcode segments and unique sequence segments are sequenced.
[0126] As mentioned elsewhere herein, although polythymidylate primer sequences are described, other targeted or random guide sequences can also be used to guide the reverse transcription reaction. Similarly, although described as releasing barcoded oligonucleotides into partitions along with the contents of lysed cells, it should be understood that in some cases, gel bead-bound oligonucleotides can be used to hybridize mRNA and capture it on the solid phase of gel beads to facilitate separation of RNA from other cellular contents.
[0127] Fig.9A904. Additional examples of barcode oligonucleotides for RNA analysis including messenger RNA (mRNA, including mRNA obtained from cells) analysis are shown in FIG. As shown, the entire oligonucleotide 902 can be coupled to a bead 904 via a releasable linkage 906 (such as a disulfide linker). The oligonucleotide may include a functional sequence for subsequent processing, such as a functional sequence 908, which may include a sequencer-specific flow cell connection sequence, such as a P5 sequence for an Illumina sequencing system; and a functional sequence 910, which may include a sequencing primer sequence, such as an R1 primer binding site for an Illumina sequencing system. A barcode sequence 912 is included in the structure for barcoding sample RNA. RNA-specific (e.g., mRNA-specific) guide sequences, such as polythymidylic acid sequences 914, are also included in the oligonucleotide structure. An anchor sequence segment (not shown) may be included to ensure that the polythymidylic acid sequence hybridizes at the sequence end of the mRNA. Additional sequence segments 916 may be provided within the oligonucleotide sequence. This additional sequence can provide a unique molecular sequence segment, for example as a random N-mer sequence that is different between individual oligonucleotides coupled to a single bead, while the barcode sequence 912 can be constant between oligonucleotides attached to a single bead. As described elsewhere herein, this unique sequence can be used to provide a unique identification of the captured starting mRNA molecule to allow quantification of the number of RNAs initially expressed, such as mRNA counting. As will be appreciated, although shown as a single oligonucleotide attached to the surface of a bead, a single bead may include tens to tens of thousands or even millions of individual oligonucleotide molecules, where, as mentioned, the barcode segment may be constant or relatively constant for a given bead, but where the variable or unique sequence segment will be different between individual beads.
[0128] In an exemplary method for analyzing cellular RNA (e.g., mRNA) and with reference to Fig.9A, the cells are co-partitioned into partitions (e.g., droplets in an emulsion) along with barcoded beads, conversion oligo 924, and other reagents (such as reverse transcriptase, reducing agent, and dNTPs). In operation 950, the cells are lysed while the barcoded oligonucleotide 902 is released from the beads (e.g., via the action of a reducing agent), and the polythymidylic acid segment 914 of the released barcode oligonucleotide is then hybridized with the polyadenylic acid tail of the mRNA 920 released from the cell. Next, in operation 952, the polythymidylic acid segment 914 is extended in a reverse transcription reaction using the mRNA as a template to produce a cDNA transcript 922 that is complementary to the mRNA and also includes each of the sequence segments 908, 912, 910, 916, and 914 of the barcode oligonucleotide. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The conversion oligonucleotide 924 can then hybridize with the additional bases added to the cDNA transcript and promote template switching. Then the sequence complementary to the conversion oligonucleotide sequence can be incorporated into the cDNA transcript 922 via using the conversion oligonucleotide 924 as a template to extend the cDNA transcript 922. In any given partition, all cDNA transcripts of a single mRNA molecule will include a common code sequence segment 912. However, by including a unique random N-mer sequence 916, the transcripts obtained by different mRNA molecules in a given partition will be different at this unique sequence. As described elsewhere herein, this provides quantitative features that can be identified even after any subsequent amplification of the contents of a given partition, such as the number of unique segments associated with a common barcode can indicate the amount of mRNA derived from a single partition and therefore derived from a single cell. After operation 952, the cDNA transcript 922 is then amplified with primers 926 (e.g., PCR primers) in operation 954. Then, the amplified product is then purified in operation 956 (e.g., via solid phase reversible fixation (SPRI)). At operation 958, the amplified product is then sheared, connected to an additional functional sequence, and further amplified (e.g., via PCR). The functional sequence may include a sequencer-specific flow cell connection sequence 930, such as a P7 sequence for an Illumina sequencing system; and a functional sequence 928, which may include a sequencing primer binding site, such as an R2 primer for an Illumina sequencing system; and a functional sequence 932, which may include a sample index, such as an i7 sample index sequence for an Illumina sequencing system. In some cases, operations 950 and 952 may be performed in a partition, while operations 954, 956, and 958 may be performed in a bulk solution (e.g., in a pooled mixture outside a partition). In the case where the partition is a droplet in an emulsion, the emulsion may be disrupted and the contents of the droplets may be pooled to complete operations 954, 956, and 958.In some cases, operation 954 can be completed in a partition. In some cases, the barcode oligonucleotide can be digested with an exonuclease after the emulsion is destroyed. Exonuclease activity can be triggered by ethylenediaminetetraacetic acid (EDTA) after primer digestion. Although the specific sequence references for some sequencing systems (such as Illumina systems) are described, it should be understood that reference to these sequences is only for illustrative purposes, and the methods described herein can be configured to be used with other sequencing systems, and the other sequencing systems are also useful for those systems (such as systems available from Ion Torrent, Oxford Nanopore, Genia, Pacific Biosciences, Complete Genomics, etc.) Specific guides, connections, indexes and other operating sequences.
[0129] In such Fig.9A In an alternative example of a barcode oligonucleotide for RNA (e.g., cellular RNA) analysis shown in , functional sequence 908 can be a P7 sequence, and functional sequence 910 can be an R2 primer binding site. In addition, for an Illumina sequencing system, functional sequence 930 can be a P5 sequence, functional sequence 928 can be an R1 primer binding site, and functional sequence 932 can be an i5 sample index sequence. The configuration of the construct generated by such a barcode oligonucleotide can help minimize (or avoid) sequencing of polythymidylic acid sequences during sequencing.
[0130] Fig. 9B Another exemplary method for RNA analysis (including cellular mRNA analysis) is shown in FIG. In this method, conversion oligonucleotides 924 are co-distributed with individual cells and barcoded beads along with reagents such as reverse transcriptase, reducing agents, and dNTPs into partitions (e.g., droplets in an emulsion). The conversion oligonucleotides 924 may be labeled with an additional label 934 (e.g., biotin). In operation 951, the cells are lysed while the barcoded oligonucleotides 902 (e.g., Fig.9A) is released from the beads (e.g., via the action of a reducing agent). In some cases, sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site. In other cases, sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site. Next, the polythymidylic acid segment 914 of the released barcode oligonucleotide hybridizes with the polyadenylic acid tail of the mRNA 920 released from the cell. In operation 953, the polythymidylic acid segment 914 is then extended in a reverse transcription reaction using the mRNA as a template to produce a cDNA transcript 922 complementary to the mRNA, and also includes each of the sequence segments 908, 912, 910, 916, and 914 of the barcode oligonucleotide. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The conversion oligonucleotide 924 can then hybridize with the cDNA transcript and promote template switching. A sequence complementary to the conversion oligonucleotide sequence can then be incorporated into the cDNA transcript 922 by extending the cDNA transcript 922 using the conversion oligonucleotide 924 as a template. Next, a separation operation 960 can be used to separate the cDNA transcript 922 from the reagents and oligonucleotides in the partition. An additional tag 934 (e.g., biotin) can be contacted with an interactive tag 936 (e.g., streptavidin), which can be attached to a magnetic bead 938. At operation 960, the cDNA can be isolated using a pull-down operation (e.g., via magnetic separation, centrifugation), then amplified in operation 955 (e.g., via PCR), subsequently purified in operation 957 (e.g., via solid phase reversible immobilization (SPRI)), and further processed in operation 959 (shearing; ligation of sequences 928, 932, and 930; and subsequent amplification (e.g., via PCR)). In some cases where sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site, sequence 930 is a P5 sequence, and sequence 928 is an R1 primer binding site, and sequence 932 is an i5 sample index sequence. In some cases where sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site, sequence 930 is a P7 sequence, and sequence 928 is an R2 primer binding site, and sequence 932 is an i7 sample index sequence. In some cases, as shown in the figure, operations 951 and 953 can be performed within the partition, and operations 960, 955, 957 and 959 can be performed in the bulk solution (e.g., in a pooled mixture outside the partition). In the case where the partition is a droplet in an emulsion, the emulsion is destroyed and the contents of the droplet are pooled to complete operation 960. Operations 955, 957 and 959 can then be performed after operation 960 after the transcripts are pooled for processing.
[0131] Fig. 9CAnother exemplary method for RNA analysis, including cellular mRNA analysis, is shown in FIG. In this method, conversion oligonucleotides 924 are co-distributed with individual cells and barcoded beads along with reagents such as reverse transcriptase, reducing agents, and dNTPs in partitions (e.g., droplets in an emulsion). In operation 961, the cells are lysed while barcoded oligonucleotides 902 (e.g., Fig.9A) is released from the beads (e.g., via the action of a reducing agent). In some cases, sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site. In other cases, sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site. Then, the polythymidylic acid segment 914 of the released barcode oligonucleotide is then hybridized with the polyadenylic acid tail of the mRNA 920 released from the cell. Then, in operation 963, the polythymidylic acid segment 914 is then extended in a reverse transcription reaction using the mRNA as a template to produce a cDNA transcript 922 complementary to the mRNA, and also includes each of the sequence segments 908, 912, 910, 916, and 914 of the barcode oligonucleotide. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The conversion oligonucleotide 924 can then hybridize with the cDNA transcript and promote template switching. A sequence complementary to the conversion oligonucleotide sequence can then be incorporated into the cDNA transcript 922 by extending the cDNA transcript 922 using the conversion oligonucleotide 924 as a template. After operations 961 and 963, the mRNA 920 and cDNA transcript 922 are denatured in operation 962. At operation 964, the second strand is extended from a primer 940 having an additional tag 942 (e.g., biotin) and hybridized to the cDNA transcript 922. Also in operation 964, the biotin-labeled second strand can be contacted with an interactive tag 936 (e.g., streptavidin), which can be attached to a magnetic bead 938. The cDNA can be isolated using a pull-down operation (e.g., via magnetic separation, centrifugation), then amplified in operation 965 (e.g., via polymerase chain reaction (PCR)), then purified in operation 967 (e.g., via solid phase reversible immobilization (SPRI)), and further processed in operation 969 (shearing; ligation of sequences 928, 932, and 930; and subsequent amplification (e.g., via PCR)). In some cases where sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site, sequence 930 is a P5 sequence, and sequence 928 is an R1 primer binding site, and sequence 932 is an i5 sample index sequence. In some cases where sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site, sequence 930 is a P7 sequence, and sequence 928 is an R2 primer binding site, and sequence 932 is an i7 sample index sequence. In some cases, operations 961 and 963 may be performed in a partition, while operations 962, 964, 965, 967, and 969 may be performed in the body (e.g., outside the partition). In the case where the partition is a droplet in an emulsion, the emulsion may be broken and the contents of the droplet may be pooled to complete operations 962, 964, 965, 967, and 969.
[0132] Fig.9D Another exemplary method for RNA analysis, including cellular mRNA analysis, is shown in FIG. In this method, conversion oligonucleotides 924 are co-distributed with individual cells and barcoded beads along with reagents such as reverse transcriptase, a reducing agent, and dNTPs. In operation 971, the cells are lysed while barcoded oligonucleotides 902 (e.g., Fig.9A) is released from the beads (e.g., via the action of a reducing agent). In some cases, sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site. In other cases, sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site. Then, the polythymidylic acid segment 914 of the released barcode oligonucleotide is then hybridized with the polyadenylic acid tail of the mRNA 920 released from the cell. Then, in operation 973, the polythymidylic acid segment 914 is then extended in a reverse transcription reaction using the mRNA as a template to produce a cDNA transcript 922 complementary to the mRNA, and also includes each of the sequence segments 908, 912, 910, 916, and 914 of the barcode oligonucleotide. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The conversion oligonucleotide 924 can then hybridize with the cDNA transcript and promote template switching. A sequence complementary to the conversion oligonucleotide sequence can then be incorporated into the cDNA transcript 922 by extending the cDNA transcript 922 using the conversion oligonucleotide 924 as a template. In operation 966, the mRNA 920, cDNA transcript 922, and conversion oligonucleotide 924 can be denatured, and the cDNA transcript 922 can be hybridized with a capture oligonucleotide 944 labeled with an additional tag 946 (e.g., biotin). In this operation, the biotin-labeled capture oligonucleotide 944 hybridized to the cDNA transcript can be contacted with an interactive tag 936 (e.g., streptavidin), which can be attached to a magnetic bead 938. After separation from other materials (e.g., excess barcoded oligonucleotides) using a pull-down operation (e.g., via magnetic separation, centrifugation), the cDNA transcript can be amplified with primer 926 at operation 975 (e.g., via PCR), then purified in operation 977 (e.g., via solid phase reversible immobilization (SPRI)), and further processed in operation 979 (shearing; ligation of sequences 928, 932, and 930; and subsequent amplification (e.g., via PCR)). In some cases where sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site, sequence 930 is a P5 sequence, and sequence 928 is an R1 primer binding site, and sequence 932 is an i5 sample index sequence. In other cases where sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site, sequence 930 is a P7 sequence, and sequence 928 is an R2 primer binding site, and sequence 932 is an i7 sample index sequence. In some cases, operations 971 and 973 can be performed in the partitions, while operations 966, 975, 977 (purification), and 979 can be performed in the main body (e.g., outside the partitions). In the case where the partitions are droplets in an emulsion, the emulsion can be broken and the contents of the droplets can be pooled to complete operations 966, 975, 977, and 979.
[0133] Fig.9E Another exemplary method for RNA analysis, including cellular RNA analysis, is shown in . In this method, single cells are co-distributed into partitions (e.g., droplets in an emulsion) along with barcoded beads, conversion oligonucleotides 990, and other reagents (such as reverse transcriptase, reducing agents, and dNTPs). In operation 981, the cells are lysed while the barcoded oligonucleotides (e.g., Fig.9A902 shown in ) is released from the beads (e.g., via the action of a reducing agent). In some cases, sequence 908 is a P7 sequence, and sequence 910 is an R2 primer binding site. In other cases, sequence 908 is a P5 sequence, and sequence 910 is an R1 primer binding site. Then, the polythymidylic acid segment of the released barcode oligonucleotide is then hybridized with the polyadenylic acid tail of the mRNA 920 released from the cell. Then, at operation 983, the polythymidylic acid segment is then extended in a reverse transcription reaction to produce a cDNA transcript 922 complementary to the mRNA, and also includes each of the sequence segments 908, 912, 910, 916, and 914 of the barcode oligonucleotide. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The conversion oligonucleotide 990 can then hybridize with the cDNA transcript and promote template switching. A sequence complementary to the conversion oligonucleotide sequence and including a T7 promoter sequence may be incorporated into cDNA transcript 922. At operation 968, a second strand is synthesized, and at operation 970, the T7 promoter sequence may be used by a T7 polymerase in an in vitro transcription to produce an RNA transcript. At operation 985, the RNA transcript may be purified (e.g., via solid phase reversible immobilization (SPRI)), reverse transcribed to form DNA transcripts, and a second strand may be synthesized for each of the DNA transcripts. In some cases, prior to purification, the RNA transcript may be contacted with a DNA enzyme (e.g., DNA enzyme I) to decompose residual DNA. At operation 987, the DNA transcript is then fragmented and ligated to additional functional sequences, such as sequences 928, 932, and 930, and in some cases, further amplified (e.g., via PCR). In some cases where sequence 908 is a P7 sequence and sequence 910 is an R2 primer binding site, sequence 930 is a P5 sequence, and sequence 928 is an R1 primer binding site, and sequence 932 is an i5 sample index sequence. In some cases where sequence 908 is a P5 sequence and sequence 910 is an R1 primer binding site, sequence 930 is a P7 sequence, and sequence 928 is an R2 primer binding site, and sequence 932 is an i7 sample index sequence. In some cases, before removing a portion of the DNA transcript, the DNA transcript may be contacted with an RNase to decompose residual RNA. In some cases, operations 981 and 983 may be performed in a partition, while operations 968, 970, 985, and 987 may be performed in a main body (e.g., outside a partition). In the case where the partition is a droplet in an emulsion, the emulsion may be destroyed and the contents of the droplets may be pooled to complete operations 968, 970, 985, and 987.
[0134] Fig.10, another example of barcode oligonucleotides for RNA analysis including messenger RNA (mRNA, including mRNA obtained from cells) analysis is shown. As shown, the entire oligonucleotide 1002 is coupled to a bead 1004 via a releasable linkage 1006 (such as a disulfide linker). The oligonucleotide may include a functional sequence for subsequent processing, such as a functional sequence 1008, which may include a sequencer-specific flow cell connection sequence, such as a P7 sequence; and a functional sequence 1010, which may include a sequencing primer sequence, such as an R2 primer binding site. A barcode sequence 1012 is included in the structure for barcoding sample RNA. RNA-specific (e.g., mRNA-specific) guide sequences, such as polythymidylic acid sequences 1014, may be included in the oligonucleotide structure. An anchor sequence segment (not shown) may be included to ensure that the polythymidylic acid sequence hybridizes at the sequence end of the mRNA. An additional sequence segment 1016 may be provided within the oligonucleotide sequence. As described elsewhere herein, this additional sequence may provide a unique molecular sequence segment. Additional functional sequences 1020 may be included for in vitro transcription, such as a T7 RNA polymerase promoter sequence. As will be appreciated, although shown as a single oligonucleotide attached to the surface of a bead, a single bead may include tens to thousands or even millions of individual oligonucleotide molecules, where, as mentioned, the barcode segment may be constant or relatively constant for a given bead, but where the variable or unique sequence segment will differ between individual beads.
[0135] In an exemplary method of cellular RNA analysis and with reference to Fig.10, the cells are co-partitioned into partitions (e.g., droplets in an emulsion) along with barcoded beads and other reagents (such as reverse transcriptase, reducing agent, and dNTPs). In operation 1050, the cells are lysed while the barcoded oligonucleotide 1002 is released from the beads (e.g., via the action of a reducing agent), and the poly-thymidylic acid segment 1014 of the released barcode oligonucleotide is then hybridized with the poly-adenylic acid tail of the mRNA 1020. Next, at operation 1052, the poly-thymidylic acid segment is then extended using the mRNA as a template in a reverse transcription reaction to produce a cDNA transcript 1022 of the mRNA, and also includes each of the sequence segments 1020, 1008, 1012, 1010, 1016, and 1014 of the barcode oligonucleotide. Within any given partition, all cDNA transcripts of a single mRNA molecule will include a common barcode sequence segment 1012. However, by including a unique random N-mer sequence, the transcripts obtained by different mRNA molecules in a given partition will be different at this unique sequence. As described elsewhere herein, this provides a quantitative feature that can be identified even after any subsequent amplification of the contents of a given partition, such as the number of unique segments associated with a common barcode can indicate the amount of mRNA derived from a single partition and therefore from a single cell. At operation 1054, the second chain is synthesized, and at operation 1056, the T7 promoter sequence can be used by T7 polymerase in in vitro transcription to produce RNA transcripts. At operation 1058, the transcript is fragmented (e.g., sheared), connected to an additional functional sequence, and reverse transcribed. The functional sequence may include a sequencer-specific flow cell connection sequence 1030, such as a P5 sequence; and a functional sequence 1028, which may include a sequencing primer, such as an R1 primer binding sequence; and a functional sequence 1032, which may include a sample index, such as an i5 sample index sequence. At operation 1060, the RNA transcripts can be reverse transcribed to DNA, the DNA amplified (e.g., via PCR), and sequenced to identify the sequence of the cDNA transcript of the mRNA, as well as to sequence the barcode segments and unique sequence segments. In some cases, operations 1050 and 1052 can be performed in the partitions, while operations 1054, 1056, 1058, and 1060 can be performed in the body (e.g., outside the partitions). In the case where the partitions are droplets in an emulsion, the emulsion can be disrupted and the contents of the droplets pooled to complete operations 1054, 1056, 1058, and 1060.
[0136] In such Fig.10In an alternative example of a barcode oligonucleotide for RNA (e.g., cellular RNA) analysis shown in , functional sequence 1008 can be a P5 sequence, and functional sequence 1010 can be an R1 primer binding site. In addition, functional sequence 1030 can be a P7 sequence, functional sequence 1028 can be an R2 primer binding site, and functional sequence 1032 can be an i7 sample index sequence.
[0137] Fig.11 100 is a barcode oligonucleotide for RNA analysis including messenger RNA (mRNA, including mRNA obtained from cells). As shown, the entire oligonucleotide 1102 is coupled to the bead 1104 via a releasable linkage 1106 (such as a disulfide linker). The oligonucleotide may include a functional sequence for subsequent processing, such as a functional sequence 1108, which may include a sequencer-specific flow cell connection sequence, such as a P5 sequence; and a functional sequence 1110, which may include a sequencing primer sequence, such as an R1 primer binding site. In some cases, sequence 1108 is a P7 sequence, and sequence 1110 is an R2 primer binding site. A barcode sequence 1112 is included in the structure for barcoding sample RNA. An additional sequence segment 1116 may be provided within the oligonucleotide sequence. In some cases, as described elsewhere herein, this additional sequence may provide a unique molecular sequence segment. Additional sequences 1114 may be included to facilitate template switching, such as polyguanylate. As will be appreciated, while shown as a single oligonucleotide attached to the surface of a bead, a single bead may comprise tens to thousands or even millions of individual oligonucleotide molecules, wherein, as mentioned, the barcode segments may be constant or relatively constant for a given bead, but wherein variable or unique sequence segments will differ between individual beads.
[0138] In an exemplary method of cellular mRNA analysis and with reference to Fig.11, the cells are co-distributed to partitions (e.g., droplets in an emulsion) along with barcoded beads, polythymidylic acid sequences, and other reagents (such as reverse transcriptase, reducing agents, and dNTPs). In operation 1150, the cells are dissolved while the barcoded oligonucleotides are released from the beads (e.g., via the action of a reducing agent), and the polythymidylic acid sequences are hybridized with the polyadenylic acid tails of the mRNA 1120 released from the cells. Next, in operation 1152, the mRNA is then used as a template in a reverse transcription reaction to extend the polythymidylic acid sequence to produce a cDNA transcript 1122 complementary to the mRNA. The terminal transferase activity of the reverse transcriptase can add additional bases to the cDNA transcript (e.g., polycytidylic acid). The additional bases (e.g., polycytidylic acid) added to the cDNA transcript can then hybridize with 1114 of the barcoded oligonucleotide. This can promote template switching, and sequences complementary to the barcode oligonucleotides can be incorporated into the cDNA transcript. The transcripts can be further processed (e.g., amplified, partially removed, additional sequences added, etc.) and characterized, for example, by sequencing, as described elsewhere herein. The configuration of the constructs generated by such methods can help minimize (or avoid) sequencing of polythymidylate sequences during sequencing.
[0139] Fig. 12A12 is an additional example of a barcode oligonucleotide for RNA analysis including cellular RNA analysis. As shown, the entire oligonucleotide 1202 is coupled to the bead 1204 via a releasable linkage 1206 (such as a disulfide linker). The oligonucleotide may include a functional sequence for subsequent processing, such as a functional sequence 1208, which may include a sequencer-specific flow cell connection sequence, such as a P5 sequence; and a functional sequence 1210, which may include a sequencing primer sequence, such as an R1 primer binding site. In some cases, sequence 1208 is a P7 sequence, and sequence 1210 is an R2 primer binding site. A barcode sequence 1212 is included in the structure for barcoding sample RNA. An additional sequence segment 1216 may be provided within the oligonucleotide sequence. In some cases, as described elsewhere herein, this additional sequence may provide a unique molecular sequence segment. As will be appreciated, although shown as a single oligonucleotide attached to the surface of the bead, a single bead may include tens to tens of thousands or even millions of single oligonucleotide molecules, where, as mentioned, the barcode segment may be constant or relatively constant for a given bead, but where the variable or unique sequence segments will be different between individual beads. In an exemplary method for analyzing cellular RNA using this barcode, cells are co-distributed to partitions (e.g., droplets in an emulsion) along with barcoded beads and other reagents (such as RNA ligases and reducing agents). The cells are dissolved while the barcoded oligonucleotides are released from the beads (e.g., via the action of a reducing agent). The barcoded oligonucleotides can then be connected to the 5' end of the mRNA transcript by RNA ligase while in the partition. Subsequent operations may include purification (e.g., via solid phase reversible fixation (SPRI)) and further processing (shearing, connection of functional sequences, and subsequent amplification (e.g., via PCR)), and these operations may be performed in the main body (e.g., outside the partition). In the case of partitioning into droplets in an emulsion, the emulsion can be broken and the contents of the droplets pooled for additional manipulation.
[0140] Fig. 12B12 is an example of an additional barcode oligonucleotide for RNA analysis including cellular RNA analysis. As shown, the entire oligonucleotide 1222 is coupled to a bead 1224 via a releasable linkage 1226 (such as a disulfide linker). The oligonucleotide may include a functional sequence for subsequent processing, such as a functional sequence 1228, which may include a sequencer-specific flow cell connection sequence, such as a P5 sequence; and a functional sequence 1230, which may include a sequencing primer sequence, such as an R1 primer binding site. In some cases, sequence 1228 is a P7 sequence, and sequence 1230 is an R2 primer binding site. A barcode sequence 1232 is included in the structure for barcoding sample RNA. A guide sequence 1234 (e.g., a random guide sequence), such as a random hexamer, may also be included in the oligonucleotide structure. An additional sequence segment 1236 may be provided within the oligonucleotide sequence. In some cases, as described elsewhere herein, this additional sequence provides a unique molecular sequence segment. As will be appreciated, although shown as a single oligonucleotide attached to the surface of a bead, a single bead may include tens to thousands or even millions of individual oligonucleotide molecules, where, as mentioned, the barcode segment may be constant or relatively constant for a given bead, but where the variable or unique sequence segment will differ between individual beads. Fig. 12BIn an exemplary method for analyzing cell mRNA using barcoded oligonucleotides, cells are co-distributed into partitions (e.g., droplets in an emulsion) along with barcoded beads and additional reagents (such as reverse transcriptase, reducing agents, and dNTPs). The cells are lysed while the barcoded oligonucleotides are released from the beads (e.g., via the action of a reducing agent). In some cases, sequence 1228 is a P7 sequence and sequence 1230 is an R2 primer binding site. In other cases, sequence 1228 is a P5 sequence and sequence 1230 is an R1 primer binding site. The guide sequence 1234 of the random hexamer can randomly hybridize to the cell mRNA. The random hexamer sequence can then be extended in a reverse transcription reaction using mRNA from the cell as a template to produce a cDNA transcript complementary to the mRNA, and also includes each of the sequence segments 1228, 1232, 1230, 1236, and 1234 of the barcode oligonucleotide. Subsequent manipulations may include purification (e.g., via solid phase reversible immobilization (SPRI)), further processing (chopping, ligation of functional sequences, and subsequent amplification (e.g., via PCR)), and these manipulations may be performed in the bulk (e.g., outside the partitions). In the case where the partitions are droplets in an emulsion, the emulsion may be disrupted and the contents of the droplets pooled for additional manipulations. Additional reagents that may be co-dispensed with the barcoded beads may include oligonucleotides for blocking ribosomal RNA (rRNA) and nucleases for digesting genomic DNA and cDNA from cells. Alternatively, rRNA removers may be applied during additional processing operations. The configuration of constructs produced by such methods may help minimize (or avoid) sequencing of polythymidylic acid sequences during sequencing.
[0141] The single cell analysis method described here can also be applied to analyze the whole transcriptome. Fig. 12B barcode, the guide sequence 1234 may be a random N-mer. In some cases, sequence 1228 is a P7 sequence, and sequence 1230 is an R2 primer binding site. In other cases, sequence 1228 is a P5 sequence, and sequence 1230 is an R1 primer binding site. In an exemplary method for full transcriptome analysis using this barcode, a single cell is co-assigned to a partition (e.g., a droplet in an emulsion) together with barcoded beads, polythymidylic acid sequences, and other reagents (such as reverse transcriptase, polymerase, reducing agent, and dNTP). In the operation of this method, the cell is dissolved, and the barcoded oligonucleotide is released from the beads (e.g., via the action of a reducing agent), and the polythymidylic acid sequence is hybridized with the polyadenylic acid tail of the cell mRNA. In a reverse transcription reaction using mRNA as a template, a cDNA transcript of the cell mRNA can be generated. RNA can then be degraded with RNase. The guide sequence 1234 in the barcoded oligonucleotide can then be randomly hybridized with the cDNA transcript. Can be similar to Figure 3 As shown in FIG, the oligonucleotides are extended using a polymerase and other extension reagents co-distributed with beads and cells to produce a Figure 3 (F) shows an exemplary amplification product (e.g., a barcoded fragment). In some cases, the barcoded nucleic acid fragments can be further processed (e.g., amplification, additional sequence addition, cleanup processes, etc. as described elsewhere herein), such as by sequence analysis and characterization. In this operation, the sequencing signal can be from the full-length RNA.
[0142] Although operations using various barcode designs have been discussed individually, a single bead can include barcode oligonucleotides of various designs for simultaneous use.
[0143] In addition to characterizing individual cells or subpopulations of cells from a larger population, the methods and systems described herein can also be used to characterize individual cells as a way to provide an overall profile of a population of cells or other organisms. A variety of applications require the assessment of the presence of different cell or organism types within a cell population and quantification thereof, including, for example, microbiome analysis and characterization, environmental testing, food safety testing, epidemiological analysis (e.g., when tracing contamination), etc. In particular, the analytical methods described above can be used to individually characterize sequences and / or identify a large number of individual cells within a population. This characterization can then be used to assemble the overall profile of the origin population, which can provide important prognostic and diagnostic information.
[0144] For example, changes in the human microbiome (including, for example, intestinal, cheek, epidermal microbiome, etc.) have been identified as diagnostic and prognostic information for different pathologies or overall health status. Using the single cell analysis methods and systems described herein, again, individual cells in the entire population can be characterized, sequenced, and identified, and changes within the population can be identified, which can indicate diagnostically relevant factors. For example, sequencing of the bacterial 16S ribosomal RNA gene has been used as a highly accurate method for bacterial systematic classification. Using the targeted amplification and sequencing methods described above can provide identification of individual cells within a cell population. The number of different cells within a population can be further quantified to identify the current state or changes in state over time. See, for example, Morgan et al., PLoS Comput. Biol., Chapter 12, December 2012, 8(12):e1002808 and Ram et al., Syst. Biol. Reprod. Med., June 2011, 57(3):162-170, each of which is incorporated herein by reference in its entirety for all purposes. Similarly, identification and diagnosis of infection or potential infection may also benefit from the single cell analysis described herein, for example, for identifying microbial species present in larger mixtures of other cells or other biological materials, cells and / or nucleic acids (including the environments described above and any other diagnostically relevant environments, such as cerebrospinal fluid, blood, stool or intestinal samples, etc.).
[0145] The foregoing analysis may also be particularly useful for characterizing the potential drug resistance of different cells (e.g., cancer cells, bacterial pathogens, etc.) by analyzing the distribution and pattern of different resistance markers / mutations between cell populations in a given sample. In addition, characterization of changes in these markers / mutations over time between cell populations may provide valuable insights into the progression, alteration, prevention, and treatment of a variety of diseases characterized by such drug resistance issues.
[0146] Although described in terms of cells, it is to be understood that any of a variety of individual organisms or components of organisms are encompassed within this description, including, for example, cells, viruses, organelles, cell inclusions, vesicles, etc. Additionally, where reference is made to a cell, it is to be understood that such reference includes any type of cell, including, but not limited to, prokaryotic cells, eukaryotic cells, bacteria, fungi, plants, mammalian or other animal cell types, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from a unicellular or multicellular organism.
[0147] Similarly, analysis of various environmental samples for the presence of microbial organisms, viruses or other biological contaminants within such samples can provide important information regarding disease epidemiology and potentially aid in predicting disease outbreaks, epidemics of infectious diseases.
[0148] As described above, other aspects of single cells or cell colonies can also be analyzed and characterized using methods, systems, and compositions described herein. In an exemplary method, a sample containing cells to be analyzed and characterized about cell surface proteins is provided. A library of antibodies, antibody fragments, or other molecules having binding affinity to cell surface proteins or antigens (or other cell features) (also referred to herein as cell surface feature binding bases) to be characterized by cells is also provided. For ease of discussion, these affinity bases are referred to herein as binding bases. The binding base may include a reporter molecule indicating the cell surface feature thing that the binding base is combined with. Specifically, the binding base type specific to a type of cell surface feature thing will include a first reporter molecule, and the binding base type specific to different cell surface feature things will have different reporter molecules associated with it. In some aspects, these reporter molecules will include oligonucleotide sequences. Oligonucleotide-based reporter molecules provide the advantage of being able to produce significant diversity in terms of sequence, while also easily being able to be connected to most biomolecules, such as antibodies, etc., and easily detected, such as using sequencing or array technology. In an exemplary method, the binding base includes an oligonucleotide connected thereto. Therefore, the first binding base type (e.g., an antibody to a cell surface feature of the first type) will be associated with a reporter oligonucleotide having a first nucleotide sequence. Different binding base types (e.g., antibodies with binding affinity to other different cell surface features) will be associated with reporter oligonucleotides comprising different nucleotide sequences (e.g., having partial or completely different nucleotide sequences). In some cases, for various types of cell surface feature binding bases (e.g., antibodies or antibody fragments), the reporter oligonucleotide sequence may be known and easily recognizable as being associated with a known cell surface feature binding base. These oligonucleotides may be directly coupled to a binding base, or they may be connected to beads, molecular lattices (e.g., linear, spherical, cross-linked or other polymers) or other frameworks connected to or otherwise associated with a binding base, which allows multiple reporter oligonucleotides to be connected to a single binding base.
[0149] In the case where multiple reporter molecules are coupled to a single binding group, such reporter molecules may comprise the same sequence, or a specific binding group will include a known set of reporter oligonucleotide sequences. The reporter molecules may be different between different binding groups that are specific for, for example, different cell surface features and may be attributed to a specific binding group.
[0150] The reporter group can be linked to the binding group by any of a variety of direct or indirect, covalent or non-covalent associations or linkages. For example, in the case of an oligonucleotide reporter group associated with an antibody-based binding group, chemical conjugation techniques (such as those available from Innova Biosciences) can be used. Antibody labeling kits) and other non-covalent attachment mechanisms (e.g., using biotinylated antibodies and oligonucleotides (or beads comprising one or more biotinylated linkers coupled to oligonucleotides) plus avidin or streptavidin linkers) to covalently attach such oligonucleotides to a portion of an antibody or antibody fragment. Antibody and oligonucleotide biotinylation techniques are available (see, e.g., Fang et al., Fluoride-CleavableBiotinylation Phosphoramidite for 5′-end-Labeling and Affinity Purification of Synthetic Oligonucleotides , Nucleic Acids Res. 2003 Jan 15;31(2):708-715, DNA 3' end biotinylation kit available from Thermo Scientific, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes). Similarly, protein and peptide biotinylation techniques have been developed and are readily available (see, e.g., U.S. Pat. No. 6,265,552, the entire disclosure of which is incorporated herein by reference in its entirety for all purposes).
[0151] Depending on the diversity of the desired reporter molecules or a given analysis, the sequence detection scheme adopted, etc., a reporter oligonucleotide with any of a series of different lengths can be provided. In some cases, the length of these reporter sequences can be greater than about 5 nucleotides, greater than about 10 nucleotides, and greater than about 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150 or even 200 nucleotides. In some cases, the length of these reporter nucleotides can be less than about 250 nucleotides, and the length is less than about 200, 180, 150, 120, 100, 90, 80, 70, 60, 50, 40 or even 30 nucleotides. In many cases, the reporter oligonucleotide can be selected to provide a barcoded product, which has been adjusted in size and is otherwise configured to be analyzed on a sequencing system. For example, it is desirable to form a length of a sequenceable product with a length required for a specific sequencing system to provide these sequences. Likewise, these reporter oligonucleotides may include additional sequence elements in addition to the reporter sequence, such as a sequencer adapter sequence, a sequencing primer sequence, an amplification primer sequence, or the complement of any of these sequences.
[0152] In operation, the cell sample is incubated with any binding molecule and its related reporter oligonucleotide for the cell surface feature of the analysis. After incubation, the cells are washed to remove unbound binding bases. After washing, the cells are assigned to separate partitions (e.g., droplets) together with the barcode-carrying beads described above, wherein each partition includes a limited number of cells, such as (in some cases) single cells. After the barcode is released from the beads, they will guide the amplification and barcoding of the reporter oligonucleotide. As mentioned above, the barcoding of the reporter molecule repeats and can additionally include functional sequences, such as primer sequences, connection sequences, etc.
[0153] The barcoded reporter oligonucleotides are then sequenced to identify which reporter oligonucleotides bind to cells within a partition. In addition, by also sequencing the associated barcode sequence, it can be identified that a given cell surface feature is likely derived from the same cell as other different cell surface features whose reporter sequences include the same barcode sequence, i.e., they are derived from the same partition.
[0154] Based on the reporter molecules from a single partition (based on the presence of the barcode sequence), the cell surface morphology of a single cell from a population of cells can then be generated. The morphology of a single cell or a population of cells can be compared to the morphology of other cells (e.g., 'normal' cells) to identify variations in cell surface features, which can provide diagnostically relevant information. In particular, these morphologies can be particularly useful for diagnosing a variety of disorders characterized by variations in cell surface receptors, such as cancer and other disorders.
[0155] IV. Devices and Systems
[0156] Also provided herein is a microfluidic device for distributing cells as described above. Such a microfluidic device may include a microfluidic device for performing a distributing process (e.g., Figure 1 and 2 Examples of particularly useful microfluidic devices are described in U.S. Provisional Patent Application No. 61 / 977,804, filed April 4, 2014, and incorporated herein by reference in its entirety for all purposes. Briefly, these microfluidic devices may include channel networks (such as those described herein) for distributing cells into separate partitions and co-distributing such cells with, for example, oligonucleotide barcode library members disposed on beads. These channel networks may be disposed within a solid body (e.g., a glass, semiconductor, or polymer body structure in which the channels are defined), wherein those channels are connected at their ends to reservoirs for receiving various input fluids and for ultimately precipitating the distributed cells, etc., from the output of the channel network. For example, and with reference to Figure 2, an aqueous suspension of cells 214 can be provided for the reservoir coupled to the channel 202 for fluid, and an aqueous suspension of beads 216 carrying oligonucleotides can be provided for the reservoir coupled to the channel 204 at the same time. Non-aqueous solutions (e.g., oils) can be provided for channel sections 206 and 208, and aqueous fluids are distributed in the form of droplets to the non-aqueous solutions at the channel joint 212. Finally, the outlet reservoir fluid can be coupled to the channel 210, and the distributed cells and beads can be delivered to the channel and harvested therefrom. As will be appreciated, although described in the form of a reservoir, it will be appreciated that the channel section can be coupled to any of a variety of different fluid sources or receiving components (including pipelines, manifolds) or other system fluid components.
[0157] Also provided are systems for controlling the flow of these fluids through a network of channels, such as by applied pressure differentials, centrifugal forces, electrokinetic pumping, capillary or gravity flow, and the like.
[0158] V. Kit
[0159] Kits for analyzing single cells or small cell populations are also provided herein. The kits may include one, two, three, four, five or more up to all dispensing fluids, including aqueous buffers and non-aqueous dispensing fluids or oils; nucleic acid barcode libraries releasably associated with beads as described herein; microfluidic devices; reagents for disrupting cell amplified nucleic acids and providing additional functional sequences on fragments of cell nucleic acids or copies thereof; and instructions for using any of the foregoing in the methods described herein.
[0160] VI. Computer Control System
[0161] The present disclosure provides a computer control system that is programmed to implement the method of the present disclosure. Fig.17 A computer system 1701 is shown, which is programmed or otherwise configured to implement the methods of the present disclosure, including nucleic acid sequencing methods, interpretation of nucleic acid sequencing data, and analysis of cellular nucleic acids (e.g., such as RNA, mRNA) and characterization of cells obtained from sequencing data. Computer system 1701 can be an electronic device of a user or a computer system remotely located relative to the electronic device. The electronic device can be a mobile electronic device.
[0162] The computer system 1701 includes a central processing unit (CPU, also referred to herein as a "processor" and "computer processor") 1705, which may be a single-core or multi-core processor, or multiple processors for parallel processing. The computer system 1701 also includes a memory or storage location 1710 (e.g., random access memory, read-only memory, flash memory), an electronic storage unit 1715 (e.g., a hard disk), a communication interface 1720 (e.g., a network adapter) for communicating with one or more other systems, and peripheral devices 1725, such as cache, other memory, data storage, and / or an electronic display adapter. The memory 1710, storage unit 1715, interface 1720, and peripheral devices 1725 communicate with the CPU 1705 via a communication bus (solid lines) (such as a motherboard). The storage unit 1715 may be a data storage unit (or data repository) for storing data. The computer system 1701 may be operably coupled to a computer network ("network") 1730 with the aid of the communication interface 1720. The network 1730 may be the Internet, the Internet and / or an extranet, or an intranet and / or an extranet communicating with the Internet. The network 1730 may be a telecommunications and / or data network in some cases. The network 1730 may include one or more computer servers that may implement distributed computing, such as cloud computing. The network 1730 may implement a peer-to-peer network with the assistance of the computer system 1701 in some cases, and the peer-to-peer network may enable a device coupled to the computer system 1701 to act as a client or a server.
[0163] The CPU 1705 may execute a sequence of machine-readable instructions, which may be implemented in a program or software. The instructions may be stored in a storage location, such as memory 1710. The instructions may be directed to the CPU 1705, which may then be programmed or otherwise configured to implement the methods of the present disclosure. Examples of operations performed by the CPU 1705 may include fetching instructions, decoding, executing, and writing back.
[0164] CPU 1705 may be part of a circuit, such as an integrated circuit. The circuit may include one or more other components of system 1701. In some cases, the circuit is an application specific integrated circuit (ASIC).
[0165] Storage unit 1715 can store files, such as drivers, libraries, and saved programs. Storage unit 1715 can store user data, such as user preferences and user programs. Computer system 1701 may include one or more additional data storage units in some cases, which are external to computer system 1701, such as located on a remote server that communicates with computer system 1701 via an intranet or the Internet.
[0166] Computer system 1701 can communicate with one or more remote computer systems via network 1730. For example, computer system 1701 can communicate with a user's remote computer system. Examples of remote computer systems include personal computers (e.g., portable PCs), tablet or tablet PCs (e.g., iPad, Galaxy Tab), phones, smartphones (e.g. iPhone, Android can realize the installation, ) or a personal digital assistant. A user can access the computer system 1701 via the network 1730.
[0167] Methods as described herein may be implemented by machine (e.g., computer processor) executable code stored on an electronic storage location of computer system 1701, such as on memory 1710 or electronic storage unit 1715. The machine executable or machine readable code may be provided in the form of software. During use, the code may be executed by processor 1705. In some cases, the code may be retrieved from storage unit 1715 and stored on memory 1710 for access by processor 1705. In some cases, electronic storage unit 1715 may be excluded and machine executable instructions may be stored on memory 1710.
[0168] The code may be precompiled and configured for use with a machine having a processor suitable for executing the code, or compiled during runtime. The code may be provided in a programming language that may be selected so that the code can be executed in a precompiled or as-compiled manner.
[0169] Aspects of the systems and methods provided herein, such as computer system 1701, can be implemented in programming. Various aspects of the technology can be considered to be "products" or "articles" in the form of machine (or processor) executable code and / or related data that are typically executed on a type of machine-readable medium or implemented in a type of machine-readable medium. The machine executable code can be stored in an electronic storage unit, such as a memory (e.g., read-only memory, random access memory, flash memory) or a hard disk. "Storage" type media may include any or all tangible memories of a computer, processor, etc., or its related modules, such as various semiconductor memories, tape drives, disk drives, etc., which can provide non-temporary storage at any time of software programming. All or part of the software can sometimes communicate through the Internet or various other telecommunications networks. Such communications, for example, can implement software loading from one computer or processor to another, such as from a management server or host computer to an application server's computer platform. Therefore, another type of medium that can carry software elements includes light waves, radio waves, and electromagnetic waves such as those used by wired and optical landline networks and across physical interfaces between local devices via various air links. Physical elements that carry such waves (such as wired or wireless links, optical links, etc.) can also be considered media that carry the software. As used herein, unless limited to non-transitory tangible "storage" media, terms such as computer or machine "readable media" refer to any medium that participates in providing instructions to a processor for execution.
[0170] Thus, machine-readable media (such as computer executable code) can take many forms, including but not limited to tangible storage media, carrier media, or physical transmission media. Non-volatile storage media include, for example, optical or magnetic disks, such as any storage device such as can be used to implement a database, etc. in any computer shown in the drawings. Volatile storage media include dynamic memory, such as the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wires and optical fibers, including the lines that comprise the bus within a computer system. Carrier transmission media can take the form of electrical or electromagnetic signals or sound or light waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer-readable media include, for example: a floppy disk, a floppy disk, a hard disk, a magnetic tape, any other magnetic medium, a CD-ROM, a DVD or DVD-ROM, any other optical medium, a punched card tape, any other physical storage medium with a hole pattern, a RAM, a ROM, a PROM and an EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier that transmits data or instructions, a cable or link that transmits such a carrier, or any other medium from which a computer can read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
[0171] The computer system 1701 may include or be in communication with an electronic display 1735, which may include a user interface (UI) 1740 for providing results, such as nucleic acid sequencing, nucleic acid sequencing data analysis, nucleic acid sequencing sample characterization, cell characterization, etc. Examples of UIs include, but are not limited to, graphical user interfaces (GUIs) and web-based user interfaces.
[0172] The methods and systems of the present disclosure may be implemented by one or more algorithms. The algorithms may be implemented by software after being executed by the central processing unit 1705. The algorithms may, for example, trigger nucleic acid sequencing, process nucleic acid sequencing data, interpret nucleic acid sequencing results, characterize nucleic acid samples, characterize cells, etc.
[0173] The present invention provides embodiments including but not limited to the following:
[0174] 1. A method for analyzing nucleic acid from a cell, comprising:
[0175] (a) providing nucleic acid derived from a single cell into discrete partitions;
[0176] (b) generating one or more first nucleic acid sequences derived from the nucleic acid within the discrete partitions, the one or more first nucleic acid sequences having been linked to an oligonucleotide comprising a common nucleic acid barcode sequence;
[0177] (c) generating a representation of the one or more first nucleic acid sequences or one or more second nucleic acid sequences derived from the one or more first nucleic acid sequences, the one or more second nucleic acid sequences comprising the common barcode sequence; and
[0178] (d) identifying the one or more first nucleic acid sequences or the one or more second nucleic acid sequences as originating from the single cell based at least in part on the presence of the common nucleic acid barcode sequence in the representation generated in (c).
[0179] 2. The method of embodiment 1, wherein the discrete partitions are discrete droplets.
[0180] 3. The method of embodiment 1, wherein, in (a), the oligonucleotide is co-partitioned with the nucleic acid derived from the single cell into the discrete partitions.
[0181] 4. The method of embodiment 3, wherein in (a), at least 10,000 of the oligonucleotides are co-partitioned into the discrete partitions with the nucleic acid derived from the single cell.
[0182] 5. The method of embodiment 4, wherein in (a), at least 100,000 of the oligonucleotides are co-partitioned into the discrete partitions with the nucleic acid derived from the single cell.
[0183] 6. The method of embodiment 5, wherein in (a), at least 500,000 of the oligonucleotides are co-partitioned into the discrete partitions with the nucleic acid derived from the single cell.
[0184] 7. A method as described in embodiment 1, wherein, in (a), the oligonucleotides attached to beads are provided, wherein each oligonucleotide on the beads contains the same barcode sequence, and the beads are co-partitioned with the single cells into the discrete partitions.
[0185] 8. The method of embodiment 7, wherein the oligonucleotide is releasably attached to the bead.
[0186] 9. The method of embodiment 8, wherein the beads comprise degradable beads.
[0187] 10. The method of embodiment 9, further comprising, before or during (b), releasing the oligonucleotide from the bead by degrading the bead.
[0188] 11. The method of embodiment 1, further comprising, prior to (c), releasing the one or more first nucleic acid sequences from the discrete partitions.
[0189] 12. A method as described in embodiment 1, wherein (c) includes sequencing the one or more first nucleic acid sequences or the one or more second nucleic acid sequences.
[0190] 13. A method as described in embodiment 12, further comprising assembling a continuous nucleic acid sequence of at least a portion of the genome of the single cell from the sequence of the one or more first nucleic acid sequences or the one or more second nucleic acid sequences.
[0191] 14. A method as described in embodiment 13, wherein the single cell is characterized based on the nucleic acid sequence of at least a portion of the genome of the single cell.
[0192] 15. A method as described in embodiment 1, wherein the nucleic acid is released from the single cells in the discrete partitions.
[0193] 16. The method of embodiment 1, wherein the nucleic acid comprises ribonucleic acid (RNA).
[0194] 17. The method of embodiment 16, wherein the RNA is messenger RNA (mRNA).
[0195] 18. A method as described in embodiment 16, wherein (b) further comprises reverse transcribing the nucleic acid under conditions that produce the one or more first nucleic acid sequences.
[0196] 19. A method as described in embodiment 18, wherein the reverse transcription is performed in the discrete partitions.
[0197] 20. The method of embodiment 18, wherein the oligonucleotides are provided in the discrete partitions and further comprise a poly-thymidylic acid sequence.
[0198] 21. The method of embodiment 20, wherein the reverse transcription comprises hybridizing the poly-thymidylate sequence to at least a portion of each of the nucleic acids and extending the poly-thymidylate sequence in a template-directed manner.
[0199] 22. The method of embodiment 21, wherein the oligonucleotide further comprises an anchor sequence that promotes hybridization of the poly-thymidylate sequence.
[0200] 23. The method of embodiment 20, wherein the oligonucleotide further comprises a random guide sequence.
[0201] 24. A method as described in embodiment 23, wherein the random guide sequence is a random hexamer.
[0202] 25. A method as described in embodiment 24, wherein the reverse transcription comprises hybridizing the random guide sequence to at least a portion of each of the nucleic acids and extending the random guide sequence in a template-directed manner.
[0203] 26. A method as described in embodiment 1, wherein a given one of the one or more first nucleic acid sequences has sequence complementarity with at least a portion of a given one of the nucleic acids.
[0204] 27. A method as described in embodiment 1, wherein the discrete partition includes at most the single cell among a plurality of cells.
[0205] 28. The method of embodiment 1, wherein the oligonucleotide further comprises a unique molecular sequence segment.
[0206] 29. A method as described in embodiment 28, further comprising identifying a single nucleic acid sequence of the one or more first nucleic acid sequences or the one or more second nucleic acid sequences as originating from a given nucleic acid in the nucleic acids based at least in part on the presence of the unique molecular sequence segment.
[0207] 30. The method of embodiment 29, further comprising determining the amount of the given nucleic acid based on the presence of the unique molecular sequence segment.
[0208] 31. The method of embodiment 1, further comprising, before (c), adding one or more additional sequences to the one or more first nucleic acid sequences to generate the one or more second nucleic acid sequences.
[0209] 32. The method of embodiment 31, further comprising adding a first additional nucleic acid sequence to the one or more first nucleic acid sequences with the aid of a conversion oligonucleotide.
[0210] 33. A method as described in embodiment 32, wherein the conversion oligonucleotide hybridizes to at least a portion of the one or more first nucleic acid sequences and is extended in a template-directed manner to couple the first additional nucleic acid sequence to the one or more first nucleic acid sequences.
[0211] 34. The method of embodiment 33, further comprising amplifying the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence.
[0212] 35. A method as described in embodiment 34, wherein the amplification is performed in the discrete partitions.
[0213] 36. A method as described in embodiment 34, wherein the amplification is performed after releasing the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence from the discrete partitions.
[0214] 37. A method as described in embodiment 34, further comprising adding one or more second additional nucleic acid sequences to the one or more first nucleic acid sequences coupled to the first additional sequences after the amplification to produce the one or more second nucleic acid sequences.
[0215] 38. A method as described in embodiment 37, wherein the adding of the one or more second additional sequences includes removing a portion of each of the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence and coupling it to the one or more second additional nucleic acid sequences.
[0216] 39. A method as described in embodiment 38, wherein the removal is accomplished by shearing the one or more first nucleic acid sequences coupled to the first additional nucleic acid sequence.
[0217] 40. The method of embodiment 39, wherein the coupling is accomplished via ligation.
[0218] 41. The method of embodiment 18, further comprising, before (c), transcribing the one or more first nucleic acid sequences to produce one or more RNA fragments.
[0219] 42. A method as described in embodiment 41, wherein the transcription is performed after releasing the one or more first nucleic acid sequences from the discrete partitions.
[0220] 43. A method as described in embodiment 41, wherein the oligonucleotide further comprises a T7 promoter sequence.
[0221] 44. The method of embodiment 43, further comprising, before (c), removing a portion of each of the one or more RNA sequences and coupling an additional sequence to the one or more RNA sequences.
[0222] 45. The method of embodiment 44, further comprising, before (c), reverse transcribing the one or more RNA sequences coupled to the additional sequence to produce the one or more second nucleic acid sequences.
[0223] 46. The method of embodiment 45, further comprising amplifying the one or more second nucleic acid sequences before (c).
[0224] 47. The method of embodiment 41, further comprising, before (c), reverse transcribing the one or more RNA sequences to produce one or more DNA sequences.
[0225] 48. The method of embodiment 47, further comprising, before (c), removing a portion of each of the one or more DNA sequences and coupling one or more additional sequences to the one or more DNA sequences to produce the one or more second nucleic acid sequences.
[0226] 49. The method of embodiment 48, further comprising amplifying the one or more second nucleic acid sequences before (c).
[0227] 50. A method as described in embodiment 1, wherein the nucleic acid includes a complement (cDNA) produced by reverse transcription of RNA of the single cell.
[0228] 51. A method as described in embodiment 50, wherein the oligonucleotide further comprises a guide sequence and is provided in the discrete partitions.
[0229] 52. A method as described in embodiment 51, wherein the guide sequence comprises a random N-mer.
[0230] 53. A method as described in embodiment 51, wherein (b) comprises hybridizing the guide sequence to the cDNA and extending the guide sequence in a template-directed manner.
[0231] 54. The method of embodiment 1, wherein the discrete partitions comprise switch oligonucleotides comprising a complementary sequence to the oligonucleotide.
[0232] 55. The method of embodiment 54, wherein (b) comprises hybridizing the conversion oligonucleotide to at least a portion of the nucleic acid fragments derived from the nucleic acid and extending the conversion oligonucleotide in a template-directed manner.
[0233] 56. A method as described in embodiment 1, wherein (b) comprises connecting the oligonucleotide to the one or more first nucleic acid sequences.
[0234] 57. A method as described in embodiment 1, wherein the one or more first nucleic acid sequences are nucleic acid fragments derived from the nucleic acid.
[0235] 58. A method as described in embodiment 1, wherein the (b) comprises coupling the oligonucleotide to the nucleic acid.
[0236] 59. A method as described in embodiment 58, wherein the coupling includes connecting.
[0237] 60. A method as described in embodiment 1, wherein multiple partitions include the discrete partitions.
[0238] 61. A method as described in embodiment 60, wherein the multiple partitions contain less than one cell per partition on average.
[0239] 62. The method of embodiment 60, wherein less than 25% of the plurality of partitions contain no cells.
[0240] 63. A method as described in embodiment 60, wherein the plurality of partitions include discrete partitions each having at least one assigned cell.
[0241] 64. A method as described in embodiment 63, wherein less than 25% of the discrete partitions contain more than one cell.
[0242] 65. A method as described in embodiment 64, wherein at least a subset of the discrete partitions comprise beads.
[0243] 66. A method as described in embodiment 65, wherein at least 75% of the discrete partitions contain at least one cell and at least one bead.
[0244] 67. A method as described in embodiment 63, wherein the discrete partitions further comprise assigned nucleic acid barcode sequences.
[0245] 68. A method as described in embodiment 67, wherein the discrete partitions contain at least 1,000 different assigned nucleic acid barcode sequences.
[0246] 69. A method as described in embodiment 68, wherein the discrete partitions contain at least 10,000 different assigned nucleic acid barcode sequences.
[0247] 70. The method of embodiment 69, wherein the discrete partitions comprise at least 100,000 different assigned nucleic acid barcode sequences.
[0248] 71. A method as described in embodiment 60, wherein the plurality of partitions includes at least 1,000 partitions.
[0249] 72. A method as described in embodiment 71, wherein the plurality of partitions includes at least 10,000 partitions.
[0250] 73. A method as described in embodiment 72, wherein the plurality of partitions includes at least 100,000 partitions.
[0251] 74. A method of characterizing cells in a population of multiple different cell types, comprising:
[0252] (a) providing nucleic acid from single cells in the population into discrete partitions;
[0253] (b) ligating an oligonucleotide comprising a common nucleic acid barcode sequence to one or more fragments of the nucleic acid of the single cell within the discrete partitions, wherein a plurality of different partitions comprise different common nucleic acid barcode sequences;
[0254] (c) characterizing the one or more fragments of the nucleic acid from the plurality of discrete partitions and attributing the one or more fragments to a single cell based at least in part on the presence of a common barcode sequence; and
[0255] (d) characterizing a plurality of individual cells in the population based on the characterization of the one or more fragments in the plurality of discrete partitions.
[0256] 75. The method of embodiment 74, further comprising fragmenting the nucleic acid.
[0257] 76. A method as described in embodiment 74, wherein the discrete partitions are droplets.
[0258] 77. A method as described in embodiment 74, wherein characterizing the one or more fragments of the nucleic acid comprises sequencing the ribosomal deoxyribonucleic acid of the single cell, and characterizing the cell comprises identifying the cell genus, species, strain or variant.
[0259] 78. A method as described in embodiment 77, wherein the single cell is derived from a microbiome sample.
[0260] 79. A method as described in embodiment 74, wherein the single cell is derived from a human tissue sample.
[0261] 80. The method of embodiment 74, wherein the single cell is derived from a circulating cell in a mammal.
[0262] 81. The method of embodiment 74, wherein the single cell is derived from a forensic sample.
[0263] 82. The method of embodiment 74, wherein the nucleic acid is released from the individual cells in the discrete partitions.
[0264] 83. A method of characterizing a single cell or a population of cells, comprising:
[0265] (a) incubating cells with a plurality of different cell surface feature binding moieties types under conditions that allow binding between one or more cell surface feature binding moieties and their respective cell surface features (if present), wherein each different cell surface binding moiety type is capable of binding to a different cell surface feature, and wherein each different cell surface binding moiety type comprises a reporter oligonucleotide associated therewith;
[0266] (b) partitioning the cells into partitions comprising a plurality of oligonucleotides comprising a barcode sequence;
[0267] (c) linking the barcode sequence to an oligonucleotide reporter present in the partition;
[0268] (d) sequencing the oligonucleotide reporter and attached barcode; and
[0269] (e) characterizing cell surface features present on said cells based on the sequencing reporter oligonucleotides.
[0270] 84. A composition comprising a plurality of partitions, each of the plurality of partitions comprising (i) a single cell, and (ii) a population of oligonucleotides comprising a common nucleic acid barcode sequence.
[0271] 85. The composition of embodiment 84, wherein the plurality of partitions comprises droplets in an emulsion.
[0272] 86. The composition of embodiment 84, wherein the population of oligonucleotides within each of the plurality of partitions is coupled to beads disposed within each of the plurality of partitions.
[0273] 87. A composition as described in embodiment 84, wherein the single cell has been associated with a plurality of different cell surface feature binding groups associated with respective cell surface features, each different type of cell surface feature binding group comprising an oligonucleotide reporter group containing a different nucleotide sequence.
[0274] 88. A composition as described in embodiment 87, wherein the multiple different cell surface feature binding groups include multiple different antibodies or antibody fragments having binding affinity for multiple different cell surface features.
[0275] VII. Examples
[0276] Example 1 Cellular RNA Analysis Using Emulsion
[0277] In one embodiment, Fig.9A The operation shown in performs reverse transcription and cDNA amplification (via PCR) using template switching in emulsion droplets. The reaction mixture allocated for reverse transcription and cDNA amplification (via PCR) includes 1,000 cells or 10,000 cells or 10ng RNA, beads with barcoded oligonucleotides / 0.2% Tx-100 / 5xKapa buffer, 2x Kapa HS HiFi ready mix (Ready Mix), 4μM conversion oligonucleotides, and Smartscribe. In the presence of cells, the mixture is allocated so that most or all of the droplets contain a single cell and a single bead. As in operation 950, the cells are dissolved while the barcoded oligonucleotides are released from the beads, and the polythymidylic acid segments of the barcoded oligonucleotides hybridize with the polyadenylic acid tails of the mRNA released from the cells. As in operation 952, the polythymidylic acid segments are extended in the reverse transcription reaction, and the cDNA transcripts are amplified as in operation 954. Thermocycling conditions were 42°C for 130 minutes, 98°C for 2 min, and 35 cycles of the following conditions: 98°C for 15 sec, 60°C for 20 sec, and 72°C for 6 min. After thermocycling, the emulsion was disrupted and the transcripts were purified with Dynabeads and 0.6xSPRI as in procedure 956.
[0278] Fig.13A (for 1,000 cells) and Fig. 13C (for 10,000 cells) and Fig. 13B(For 10 ng RNA) (Smartscribe line) shows the yield of template switching reverse transcription and PCR in emulsion. The cDNA transcripts from RT and PCR performed on 10 ng RNA in emulsion were sheared and ligated to the functional sequence, cleaned up with 0.8x SPRI and further amplified by PCR as in operation 958. The amplification product was cleaned up with 0.8x SPRI. Fig. 13B (Line SSII) shows the yield of this treatment.
[0279] Example II Cellular RNA Analysis Using Emulsion
[0280] In another embodiment, Fig.9A The operation shown in is performed in emulsion droplets using template switching reverse transcription and cDNA amplification (via PCR). The reaction mixture allocated to perform reverse transcription and cDNA amplification (via PCR) includes Jurkat cells, beads with barcoded oligonucleotides / 0.2% TritonX-100 / 5x Kapa buffer, 2x KapaHS HiFi premix, 4μM conversion oligonucleotides and Smartscribe. The mixture is allocated so that most or all of the droplets contain a single cell and a single bead. As in operation 950, the cells are dissolved while the barcoded oligonucleotides are released from the beads, and the polythymidylic acid segments of the barcoded oligonucleotides are hybridized with the polyadenylic acid tails of the mRNA released from the cells. As in operation 952, the polythymidylic acid segments are extended in the reverse transcription reaction, and the cDNA transcripts are amplified as in operation 954. Thermocycling conditions were 42°C for 130 minutes, 98°C for 2 min, and 35 cycles of 98°C for 15 sec, 60°C for 20 sec, and 72°C for 6 min. After thermocycling, the emulsion was disrupted and transcripts were cleaned up with Dyno beads and 0.6x SPRI as in procedure 956. Fig.14A The yields of the reactions with different cell numbers (625 cells, 1,250 cells, 2,500 cells, 5,000 cells, and 10,000 cells) are shown in FIG. Fig. 14B The GADPH qPCR analysis results shown in confirm these yields.
[0281] Example III RNA analysis using emulsion
[0282] In another embodiment, similar to Fig. 9CIn the manner shown in , reverse transcription is performed in emulsion droplets and cDNA amplification is performed in the main body. The reaction mixture allocated for reverse transcription includes beads with barcoded oligonucleotides, 10ng Jurkat RNA (e.g., Jurkat mRNA), 5x first-strand buffer, and Smartscribe. As in operation 961, the barcoded oligonucleotides are released from the beads, and the polythymidylic acid segments of the barcoded oligonucleotides are hybridized with the polyadenylic acid tails of the RNA. As in operation 963, the polythymidylic acid segments are extended in the reverse transcription reaction. The thermal cycling conditions for reverse transcription are one cycle at 42° C. for 2 hours, and another cycle at 70° C. for 10 min. After the thermal cycle, the emulsion is destroyed and the RNA and cDNA transcripts are denatured as in operation 962. Then, as in operation 964, the second chain is synthesized by primer extension with a primer having a biotin tag. The reaction conditions for this primer extension include cDNA transcripts as the first chain, and the concentration of the biotinylated extension primer changes from 0.5 μM to 3.0 μM. Thermal cycling conditions were one cycle at 98°C for 3 min, and another cycle at 98°C for 15 sec, 60°C for 20 sec, and 72°C for 30 min. After primer extension, the second strand was pulled down with Dyno beads MyOne Streptavidin C1 and T1, and cleaned up with AgilentSureSelect XT buffer. The second strand was preamplified via PCR as in operation 965 under the following cycle conditions: one cycle at 98°C for 3 min, and another cycle at 98°C for 15 sec, 60°C for 20 sec, and 72°C for 30 min. Fig.15 The yields for various concentrations of biotinylated primers (0.5 μM, 1.0 μM, 2.0 μM, and 3.0 μM) are shown in FIG.
[0283] Example IV RNA Analysis Using Emulsion
[0284] In another example, if Fig.10As shown in , RNA transcripts are produced by in vitro transcription with T7 polymerase. The mixture allocated for reverse transcription includes beads with barcoded oligonucleotides that also include T7 RNA polymerase promoter sequences, 10ng human RNA (e.g., human mRNA), 5x first-strand buffer, and Smartscribe. The mixture is allocated so that most or all of the droplets contain a single bead. As in operation 1050, the barcoded oligonucleotides are released from the beads, and the polythymidylic acid segments of the barcoded oligonucleotides are hybridized with the polyadenylic acid tails of the RNA. As in operation 1052, the polythymidylic acid segments are extended in the reverse transcription reaction. The thermal cycling conditions are one cycle at 42° C. for 2 hours, and another cycle at 70° C. for 10 min. After the thermal cycle, the emulsion is destroyed and the remaining operations are performed in the main body. Then the second chain is synthesized by primer extension as in operation 1054. The reaction conditions for this primer extension include cDNA transcripts as templates and extension primers. The thermal cycling conditions were one cycle at 98°C for 3 min and another cycle at 98°C for 15 sec, 60°C for 20 sec and 72°C for 30 min. After this primer extension, the second strand was purified with 0.6x SPRI. As in operation 1056, in vitro transcription was then performed to produce RNA transcripts. In vitro transcription was allowed to proceed overnight and the transcripts were purified with 0.6x SPRI. Fig.16 The RNA yields of in vitro transcription are shown.
[0285] Although some embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided only by way of example. The present invention is not intended to be limited by the specific embodiments provided in the specification. Although the present invention has been described with reference to the above description, the description and illustration of the embodiments herein are not intended to be interpreted in a limiting sense. Those skilled in the art will appreciate many variations, changes, and substitutions without departing from the present invention. In addition, it should be understood that all aspects of the present invention are not limited to the specific description, configuration, or relative proportions set forth herein, which depend on a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein may be adopted when practicing the present invention. It is therefore contemplated that the present invention should also encompass any such substitutions, modifications, variations, or equivalents. The following claims are intended to define the scope of the present invention and thus encompass methods and structures within the scope of these claims and their equivalents.
Claims
1. A method for analyzing nucleic acid from a cell, comprising: (a) providing nucleic acid derived from a single cell into discrete partitions; (b) generating one or more first nucleic acid sequences derived from the nucleic acid within the discrete partitions, the one or more first nucleic acid sequences having been linked to an oligonucleotide comprising a common nucleic acid barcode sequence; (c) generating a representation of the one or more first nucleic acid sequences or one or more second nucleic acid sequences derived from the one or more first nucleic acid sequences, the one or more second nucleic acid sequences comprising the common barcode sequence; as well as (d) identifying the one or more first nucleic acid sequences or the one or more second nucleic acid sequences as originating from the single cell based at least in part on the presence of the common nucleic acid barcode sequence in the representation generated in (c). The method of claim 1 , wherein the discrete partitions are discrete droplets.
3. The method of claim 1, wherein: In (a), the oligonucleotides are co-partitioned with the nucleic acid derived from the single cell into the discrete partitions.
4. The method of claim 3, wherein: In (a), at least 10,000 of the oligonucleotides are co-partitioned with the nucleic acid derived from the single cell into the discrete partitions.
5. The method of claim 4, wherein: In (a), at least 100,000 of the oligonucleotides are co-partitioned with the nucleic acid derived from the single cell into the discrete partitions.
6. The method of claim 5, wherein: In (a), at least 500,000 of the oligonucleotides are co-partitioned with the nucleic acid derived from the single cell into the discrete partitions.
7. The method of claim 1, wherein: In (a), the oligonucleotides are provided attached to beads, wherein each oligonucleotide on the beads comprises the same barcode sequence, and the beads are co-partitioned with the single cells into the discrete partitions.
8. A method of characterizing cells in a population of multiple different cell types, comprising: (a) providing nucleic acid from single cells in the population into discrete partitions; (b) ligating an oligonucleotide comprising a common nucleic acid barcode sequence to one or more fragments of the nucleic acid of the single cell within the discrete partitions, wherein a plurality of different partitions comprise different common nucleic acid barcode sequences; (c) characterizing the one or more fragments of the nucleic acid from the plurality of discrete partitions and attributing the one or more fragments to a single cell based at least in part on the presence of a common barcode sequence; as well as (d) characterizing a plurality of individual cells in the population based on the characterization of the one or more fragments in the plurality of discrete partitions.
9. A method of characterizing a single cell or a cell population, comprising: (a) incubating cells with a plurality of different cell surface feature binding moieties types under conditions that allow binding between one or more cell surface feature binding moieties and their respective cell surface features (if present), wherein each different cell surface binding moiety type is capable of binding to a different cell surface feature, and wherein each different cell surface binding moiety type comprises a reporter oligonucleotide associated therewith; (b) partitioning the cells into partitions comprising a plurality of oligonucleotides comprising a barcode sequence; (c) linking the barcode sequence to an oligonucleotide reporter present in the partition; (d) sequencing the oligonucleotide reporter and the attached barcode; as well as (e) characterizing cell surface features present on said cells based on the sequencing reporter oligonucleotides.
10. A composition comprising a plurality of partitions, each of the plurality of partitions comprising (i) a single cell, and (ii) a population of oligonucleotides comprising a common nucleic acid barcode sequence.
